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a b s t r a c t
Background: Polycyclic aromatic hydrocarbons (PAHs) are potent atmospheric pollutants produced by incomplete combustion of organic materials. Pre-clinical and occupational studies have reported a positive association
of PAHs with oxidative stress, inﬂammation and subsequent development of atherosclerosis, a major underlying
risk factor for cardiovascular disease (CVD). The aim of the current study is to estimate the association between
levels of PAH biomarkers and CVD in a national representative sample of United States (US) adults.
Methods: We examined adult participants (≥20 years of age) from the merged US National Health and Nutrition
Examination Survey 2001–2010. Logistic regression models were used to estimate the associations of each urinary PAH biomarker and CVD. Post-exploratory structural equation modeling was then used to address the interdependent response variables (angina, heart attack, stroke and coronary heart disease) as well as the
interdependencies of PAH biomarkers.
Results: PAH biomarkers were positively associated with cardiovascular disease in multiple logistic regression
models, although some associations were not statistically robust. Using structural equation modeling, latent
PAH exposure variable was positively associated with latent CVD level variable in the multivariable adjusted
model (β = 0.12; 95% CI: 0.03, 0.20).
Conclusion: A modest association between levels of PAH biomarkers and CVD was detected in US adults. Further
prospective studies with adequate sample size are needed to replicate or refute our ﬁndings.
© 2016 Elsevier Ltd. All rights reserved.

1. Introduction
Despite advances in prevention, diagnosis and treatment,
cardiovascular disease (CVD) remains the number one cause of
mortality in United States (U.S.) adults (Kochanek et al., 2014). Cardiovascular disease refers to numerous conditions, many of which
are related to atherosclerosis which develops when plaque builds
up in arterial walls, narrowing the arteries, and decreasing or
sometimes completely blocking tissue blood ﬂow (Goff et al.,
2014). Such mechanisms can manifest themselves eventually with
adverse clinical outcomes such as coronary heart disease, angina
pectoris, heart attack, and stroke.
Epidemiological evidence suggests that exposure to particulate matter present in ambient air may pose an increased CVD risk in humans
(Bhatnagar, 2006). Polycyclic aromatic hydrocarbons (PAHs) are potent
atmospheric pollutants that occur in oil, coal, and tar deposits, and are
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produced as byproducts of smoking, indoors and outdoors fuel burning
and food grilling (Liu et al., 2008; Ramesh et al., 2004; Simko, 2005).
Pre-clinical studies have reported a positive association between exposure to PAHs, oxidative stress and atherosclerosis (Jeng et al., 2011;
Curfs et al., 2005). Epidemiological studies have found a positive association between biomarkers of PAH exposure and serum inﬂammatory
markers of CVD (Alshaarawy et al., 2013). In addition, a positive association between occupational exposure to PAHs and CVD morbidity and
mortality has been reported (Brucker et al., 2014; Burstyn et al.,
2005). However it is not clear if exposure to PAHs is associated with cardiovascular disease in the general population.
With advantages of recent nationally representative sample surveys
and standardized data collection approaches with relatively large samples, we examined the association of PAH exposure and CVD in the
United States (US) general population. In addition, we used Structural
Equation Modeling approach trying to account for the interdependencies that must be confronted when different PAH biomarkers are
studied all at once. We also are accounting for the shared pathogenesis
of the response variables, namely the CVD events (angina, heart attack,
stroke and coronary heart disease).
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2. Methods
2.1. Study population
The National Health and Nutrition Examination Surveys (NHANES)
consist of a series of surveys designed by the National Center for Health
Statistics to continuously monitor the health status of the U.S. civilian
non-institutionalized population (United States Centers for Disease
Control and Prevention. National Center for Health Statistics (NCHS),
2010). The NHANES survey includes a stratiﬁed multistage probability
sample. Selection is based on counties, blocks, households and individuals within households, and included oversampling of non-Hispanic
Blacks and Mexican Americans in order to provide stable estimates of
these groups. Data are collected for a two-year survey cycle.
In the current study we merged 2001–02, 2003–04, 2005–06,
2007–08 and 2009–10 data cycles, where eight analytes of PAHs
have been consistently measured. There were 27,584 participants
who were ≥ 20 years of age. Urinary PAH biomarkers were only measured in a subsample NHANES (n = 7848). Participants with missing
information on serum cotinine and other covariates were not included in the ﬁnal model. This resulted in 7301 participants included in
the ﬁnal analyses.
2.2. Outcome: Cardiovascular disease
A standardized medical condition questionnaire was administered
during the personal interview on a broad range of health conditions including coronary heart disease, angina pectoris, heart attack and stroke.
Participants were asked “has a doctor or other health professional ever
told you that you have: coronary heart disease (CHD)/angina pectoris/
heart attack/stroke?” (These were 4 separate questions with the same
wording style). A participant was considered a CVD case if she/he answered “yes” to any of the previous questions (0: no event occurrence/1: occurrence of at least one of the 4 clinical events).
2.3. Main exposure: Urinary levels of PAH biomarkers
Detailed urine specimen collection and processing instructions are
discussed in the NHANES Laboratory/Medical Technologists Procedures
Manual (United States Center for Disease Control and Prevention. National Center for Health Statistics (NCHS), 2006). Speciﬁc analytes measured in NHANES are monohydroxy-PAH (OH-PAH). The procedure
involves enzymatic hydrolysis of urine, with extraction, derivatization
and analysis using capillary gas chromatography combined with high
resolution mass spectrometry (GCHRMS). This method uses isotope dilution with carbon-13 labeled internal standards. Ions from each analyte
and each carbon-13 labeled internal standard are monitored, and the
abundance of each ion is measured. The ratios of these ions are used
as criteria for evaluating the data. By evaluating these analytes in
urine, a measurement of the body burden from PAH exposure is obtained (A detailed description is available online at http://www.cdc.gov/
nchs/data/nhanes/nhanes_03_04/l31pah_c_met.pdf).
The limit of detection (LOD) was deﬁned as the higher LOD calculated by two methods: (i) in direct relation to method blanks prepared in
parallel with the unknown samples, as 3 times the standard deviation of
the method blanks, and (ii) according to the instrumental detection
limit deﬁned as the lowest point in the calibration curve (0.5 pg/uL, or
5 pg/mL in 2-mL urine samples) veriﬁed to give a signal with the S/N
equal to or N3. The limit of detection for each biomarker and each
data cycle can be found in the corresponding NHANES PAH lab ﬁles provided as supplementary materials. b 1% of the study population has PAH
levels below lower detection limit.
Checks were made on the stability of the analytical system. Blanks
and standards, as well as quality control materials, were added to each
day's run sequence. The blank and standard were analyzed at the beginning of each run to check the system for possible contamination or in
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the spiking solutions and/or reagents. Two QCLs and two QCHs were
prepared and analyzed at the beginning and the end of each run; their
concentrations were compared with acceptance criteria to assure the
proper operation of the analysis. Relative retention times were examined for the internal standard to ensure the choice of the correct chromatographic peak. More details on quality control procedures can be
found in the online supplemental materials.
Seven urinary low molecular weight PAH analytes (1-hydroxynapthol, 2-hydroxynapthol, 2-hydroxyﬂuorene, 3-hydroxyﬂuorene,
1-hydroxyphenanthrene, 2-hydroxyphenanthrene, 3-hydroxyphenanthrene) and one urinary high molecular weight analyte (1-hydroxypyrene) were consistently available in NHANES 2001–10. Few other
biomarkers are not included in the current study because they were
not available in all years. All analytes were measured in the same unit;
ng/L. Urinary analytes of PAHs were corrected for creatinine concentration to reduce their variability by differences in urinary outputs. Urinary
levels of OH-PAH (ng/L) were divided by urinary creatinine level
(mg/dL) multiplied by 0.01, i.e., [(ng/L) ÷ (mg/dL ∗ 0.01)] and
expressed as nanogram per gram of creatinine (ng/g creatinine).
2.4. Covariates
In NHANES, information on age, gender, ethnic self-identiﬁcation
(ESI), alcohol drinking, and poverty-income ratio (PIR) were obtained
during a standardized questionnaire during a home interview. Information on anthropometric, physical and laboratory components were obtained during the medical center examination. Body mass index (kg/
m2) was calculated as weight in kilograms divided by height in meters
squared. Serum total cholesterol (mg/dL) was measured enzymatically.
Serum cotinine (ng/mL) was measured by an isotope dilution-high performance liquid chromatography atmospheric pressure chemical ionization tandem mass spectrometry.
2.5. Statistical analysis
Exploratory data analysis techniques were used to assess the univariate distribution of the study variables. Urinary PAH biomarker levels
were log-transformed as a result of their skewed distribution. We ran
logistic regression models to calculate the odds ratio ([OR] and 95% conﬁdence interval [CI]) of self-reported CVD, for each urinary OH-PAH,
controlling for age (years) and sex. Final models were additionally adjusted for ESI (non-Hispanic White, non-Hispanic Black, Hispanics, and
all others), education (less than high school, high school, and above
high school), PIR, past-year alcohol drinking, BMI (normal, overweight,
obese), total cholesterol (mg/dL), and serum cotinine (ng/mL).
Structural Equation Modeling (SEM) was then used to construct a
series of models to estimate the association of PAHs and CVD level.
Buncher et al. discussed the application of SEM in Environmental Epidemiology early in 1991 (Buncher et al., 1991). Structural equation modeling is a group of statistical methods that can model relationships
between one or more independent variables and one or more dependent variables (Ullman, 2006). In the current analysis, PAH exposure is
a latent construct that is not directly measured but rather assessed indirectly by PAH biomarkers. Instead of simply combining PAH biomarkers
by taking the sum and assigning equal weight to each biomarker, they
are employed as indicators of a latent construct and hence allows for estimation and removal of the measurement error (Ullman, 2006). Limitations of including multiple indicators of the same exposure in regression
models (such as collinearity) are accounted for in the SEM approach
(Gefen et al., 2000; Suhr, 2006). Similarly a latent construct for CVD
level was created via self-reported physician diagnosis of coronary
heart disease, angina, heart attack and/or stroke. For both constructs,
we deﬁned factor loadings of 0.4 or greater as strongly correlated indicators with the latent construct. This part of the model that relates the
measured variables to the corresponding latent construct is the measurement part of the model. The hypothesized association between
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the two constructs is considered the structural part of the model,
regressing the latent CVD level construct as the response variable
on PAHs construct. In the initial models, we used maximum likelihood estimation with robust standard errors (MLR). Because MLR
does not provide ﬁt indices, in our post-exploratory step we used a
robust weighted least squares estimator (WLSMV). We determined
goodness of ﬁt of the hypothesized models to the data by several ﬁt
indices, including comparative ﬁt index (CFI) ≥ 0.95 and root mean
square error approximation (RMSEA) ≤ 0.05. (Hu and Bentler, 1999;
Browne and Cudeck, 1992).
3. Results
Table 1 presents main characteristics of the study population. About
one half of the study population was female (51.2%). The majority of the
study population was non-Hispanic White (71.1%). The arithmetic
mean of serum cotinine was 64.1 ng/mL. Table 2 presents selected percentiles of urinary OH-PAH biomarkers.
The main estimates of the study are presented in Table 3. Individual polycyclic aromatic hydrocarbons were positively associated
with self-reported CVD. However, only 1-hydroxynaphalene, 2hydroxynaphalene, 2-hydroxyﬂuorene and 3-hydroxyﬂuorene were
statistically robust.
Fig. 1 presents the baseline conceptual model regressing the latent
construct of CVD level as the response variables on the level of PAH exposure, measured by eight urinary PAH biomarkers, controlling for age
(years) and sex. Results indicated a positive association between PAHs
and CVD (β = 0.12; 95% CI: 0.07, 0.17). The factor loadings were all
≥ 0.4 suggesting a strong correlation between the measures and each
corresponding construct.
Table 4 presents the association of PAH exposure level and CVD level
constructs additionally adjusting for ESI, education, PIR, alcohol drinking, serum cotinine, total cholesterol and BMI. Our results did not
change appreciably (β = 0.12; 95% CI: 0.03, 0.20), suggesting a positive
association between PAHs and CVD independent of the potential confounders studied here. Our results were consistent using either MLR or
WLSMV estimator. Table 4 also presents the association of PAH and
Table 1
Baseline characteristics of the study population (n = 7301). Data for the United States
adults ≥20 years of age based on the National Health and Nutrition Examination Survey
2001–2010.
Characteristics

Mean values ± std error of mean or
sample size (weighted percentages)

Age (years)
Sex (%)
Male
Female
Ethnic self-identiﬁcation (%)
Non-Hispanic White
Non-Hispanic Black
Hispanics
All others
Education (%)
Less than high school
High school
Above high school
Income-poverty ratio b 1
Past-year alcohol drinking (%)
Body mass index (kg/m2)
b25
25–29.9
≥30
Serum cotinine (ng/mL)
Total cholesterol (mg/dL)
Any CVD (%)
Coronary heart disease (%)
Angina (%)
Heart attack (%)
Stroke (%)

46.2 ± 0.3
3550 (48.8)
3751 (51.2)
3693 (71.1)
1378 (10.7)
1919 (12.8)
311 (5.4)
2079 (18.3)
1773 (25.1)
3449 (56.6)
1325 (12.6)
4527 (67.6)
2184 (32.7)
2542 (33.4)
2575 (33.9)
64.1 ± 2.8
198.8 ± 0.8
732 (7.9)
333 (3.7)
218 (2.4)
307 (3.3)
235 (2.4)

Table 2
Selected percentiles of urinary biomarkers of polycyclic aromatic hydrocarbons (ng/g creatinine) among participants included in the ﬁnal analysis. Data for the United States adults
≥20 years of age based on the National Health and Nutrition Examination Survey 2001–
2010.
Biomarkers

10th
percentile

Q1

Median

Q3

90th
percentile

1-Hydroxynaphthalene
2-Hydroxynaphthalene
2-Hydroxyﬂuorene
3-Hydroxyﬂuorene
1-Hydroxyphenanthrene
2-Hydroxyphenanthrene
3-Hydroxyphenanthrene
1-Hydroxypyrene

515
957
103
33
62
26
36
26

901
1576
142
50
90
39
53
44

2081
3114
227
86
141
61
85
83

6941
7454
609
279
231
102
158
159

17,532
15,717
1630
909
361
178
297
313

CVD constructs, stratiﬁed by sex, ESI and smoking status. Overall, PAH
was associated with CVD in the stratiﬁed subgroups, although some associations were not statistically robust. We did not detect subgroup variations in the estimates.
4. Discussion
Exposure to polycyclic aromatic hydrocarbons measured by eight
urinary PAH biomarkers exhibited a positive association with cardiovascular disease in adults ≥20 years of age independent of serum cotinine a
marker of nicotine exposure as well as other potential confounders. Our
results are consistent with ﬁndings from previous occupational studies
which reported positive associations between exposure to PAHs, and ischemic heart diseases and cardiovascular mortality in occupations that
include likely exposure to PAHs (Brucker et al., 2014; Burstyn et al.,
2005; Thériault et al., 1988; Tüchsen et al., 1996). Xu et al. used
NHANES 2001–04 and reported a positive association between PAH biomarkers and self-reported CVD using logistic regression modes (Xu
et al., 2010). In the current study, a latent CVD construct approach was
selected in addition to utilizing the standard binary approach (0: no
event occurrence/1: occurrence of at least one of the 4 clinical events)
to allow for consideration of the shared pathogenesis in the development of CHD, angina, heart attack and stroke by means of a main common mechanism, namely atherosclerosis (Soler and Ruiz, 2010). A
latent PAH variable was also used to account for the interdependencies
of the PAH biomarkers as humans are usually exposed to mixtures of
PAHs (Elovaara et al., 1995). Due to the high cost of detecting parent
PAH levels in humans, the most commonly used biomarkers of PAH exposure are urinary OH-PAH biomarkers. Urinary PAH biomarkers have
been previously found to correlate well with levels of exposure to
PAHs in the general population (Castano-Vinyals et al., 2004).
The mechanisms underlying the positive association of PAH exposure and CVD remain unknown. Upon exposure to PAHs, detoxiﬁcation

Table 3
The association of PAH biomarkers and cardiovascular disease. Data for the United States
adults ≥20 years of age based on the National Health and Nutrition Examination Survey
2001–2010.
OH-PAH (ng/g
creatinine)

Age-sex adjusted odds
ratio (95% CI)

Multivariable-adjusted
odds ratio (95% CI)a

1-Hydroxynaphthalene
2-Hydroxynaphthalene
2-Hydroxyﬂuorene
3-Hydroxyﬂuorene
1-Hydroxyphenanthrene
2-Hydroxyphenanthrene
3-Hydroxyphenanthrene
1-Hydroxypyrene

1.13 (1.07, 1.21)
1.31 (1.19, 1.45)
1.31 (1.18, 1.45)
1.21 (1.11, 1.33)
1.12 (1.00, 1.25)
1.22 (1.09, 1.37)
1.13 (1.00, 1.27)
1.20 (1.08, 1.33)

1.11 (1.04, 1.18)
1.22 (1.08, 1.38)
1.27 (1.12, 1.43)
1.18 (1.06, 1.32)
1.07 (0.94, 1.21)
1.11 (0.98, 1.26)
1.10 (0.96, 1.25)
1.12 (1.00, 1.26)

a
Adjusted for age (years), sex, ESI (non-Hispanic White, non-Hispanic Black, Hispanic
and all others), education (less than high school, high school and above high school), PIR,
past-year alcohol drinking, BMI (normal, overweight and obese), total cholesterol (mg/dL)
and serum cotinine (ng/mL).
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Fig. 1. Model depicting the hypothesized PAH exposure-CVD association. Data for the National Health and Nutrition Examination Survey 2001–2010 (n = 7301)

occurs leading to the formation of highly reactive intermediates that can
interact with the DNA (Curfs et al., 2004). Such effects of PAHs exposure
on plaque buildup in animals were found to be dose dependent (Penn
et al., 1981). Pre-clinical studies have also suggested that PAHs might
also exert their atherogenic effect via stimulation of an inﬂammatory
process involving an increased inﬂux of proinﬂammatory cells into
these plaques (Curfs et al., 2005). The role of inﬂammation as a risk
factor for CVD development has been well established (Pearson et al.,
2003; Goff et al., 2013). Population based studies supported an association between PAH and inﬂammation (Alshaarawy et al., 2013; Clark
et al., 2012). A recent study also suggested an association between
PAHs and a number of obesity-related cardiometabolic health risk factors (Ranjbar et al., 2015).

Table 4
Estimated association of polycyclic aromatic hydrocarbon exposure on cardiovascular disease level in adults (≥20+ years), stratiﬁed by participant characteristics. Data for the
United States based on the National Health and Nutrition Examination Survey 2001–2010.
Characteristics
Full sample
Sex
Male
Female
ESI
NH-White
NH-Black
Hispanic
Smoking
Never
Former
Recently active

Age-sex adjusteda
β (95% CI)

Multivariable adjustedb
β (95% CI)

0.12 (0.07, 0.17)

0.12 (0.03, 0.20)

0.06 (−0.01, 0.13)
0.18 (0.11, 0.25)

0.08 (−0.02, 0.17)
0.16 (0.07, 0.26)

0.13 (0.07, 0.19)
0.10 (0.01, 0.19)
−0.04 (−0.12, 0.04)

0.13 (0.03, 0.23)
0.15 (0.04, 0.27)
0.01 (−0.10, 0.13)

0.08 (−0.04, 0.20)
0.03 (−0.09, 0.15)
0.24 (0.09, 0.39)

0.11 (−0.01, 0.23)
0.02 (−0.10, 0.14)
0.25 (0.13, 0.37)

A WLSMV estimator was used (probit regression are estimated). Model ﬁt for each of the
three models: RMSEA b 0.05; CFI ≥ 0.95.
a
Adjusted for age and sex, except for stratiﬁed variable.
b
Adjusted for age, sex, ESI, education, PIR, alcohol drinking, serum cotinine, total cholesterol and BMI, except for stratiﬁed variable.

Several of the study limitations merit attention. Of main concern is
the cross sectional nature of NHANES which does not allow to draw
temporal or causal inferences regarding the association of PAHs and
CVD. In addition, our study does not have the data to estimate the
sources of exposure to PAHs. Urinary biomarker measurements reﬂect
recent PAH exposure as non-smoking sources of PAHs can vary dayto-day in the general population. Finally, CVD was ascertained by selfreport. Accordingly, some recall bias may exist. However, these biases
are likely to be non-differential biases, which would minimize any
observed association. Notwithstanding these limitations, the study
ﬁndings are of interest because of the inclusion of a relatively large nationally representative multiethnic sample, the NHANES standardized
data collection approaches, and the ability to adjust for potential
confounders.
In conclusion, this epidemiological evidence from the current
study tends to conﬁrm what prior research found – namely, a positive association between PAH exposure and CVD. Any claim of atherogenic effects of PAH exposure is premature, but given increased
prevalence of PAH exposure and CVD in the U.S. and elsewhere,
there is a reason to study their linkages. More probing experimentation of a clinical translational character is needed, including research
on potential mechanisms.
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Important Information for Users
The Centers for Disease Control and Prevention (CDC) periodically refines these laboratory methods. It is the
responsibility of the user to contact the person listed on the title page of each write-up before using the analytical
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PAHs in Urine

NHANES 2007-2008
This document details the Lab Protocol for NHANES 2005–2006 data.
A tabular list of the released analytes follows:

Data File Name Variable Name

SAS Label

URXPO1

1-napthol (ng/L)

URXPO2

2-napthol

URXPO3

3-fluorene

URXPO4

2-fluorene

URXPO5

3-phenanthrene

URXPO6

1-phenanthrene

URXPO7

2-phenanthrene

URXP10

1-pyrene

URXP17

9-fluorene

PAH_E

1.

Clinical Relevance and Summary of Test Principle
a. Clinical Relevance
Polycyclic aromatic hydrocarbons (PAHs) are a class of ubiquitous environmental
contaminants formed during incomplete combustion processes. Many of them have
been identified as suspected human carcinogens. Common routes of occupational
exposure may include work involving diesel fuels and coal tars such as paving and
roofing. Possible environmental exposures include smoking, diet, smog and forest
fires. Threshold levels for carcinogenicity have not been determined for most PAHs.
Application of this method to analyze samples obtained from participants in the
National Health and Nutrition Examination Survey (NHANES) will help determining
the reference range of these chemicals in general U.S. population, aged 6 years and
higher.
b. Test Principle
The specific analytes measured in this method are monohydroxy-PAH (OH-PAH).
The procedure involves enzymatic hydrolysis of urine, extraction, derivatization and
analysis using capillary gas chromatography combined with high resolution mass
spectrometry (GC-HRMS). This method uses isotope dilution with carbon-13
labeled internal standards. Ions from each analyte and each carbon-13 labeled
internal standard are monitored, and the abundances of each ion are measured.
The ratios of these ions are used as criteria for evaluating the data. The analytes
measured in this procedure are shown in Table 1. By evaluating these analytes in
urine, a measurement of the body burden from PAH exposure is obtained.
Table 1. Analytes measured, their parent compounds, and their abbreviations.

No.

2.

Parent PAH

Metabolite/Analyte

Abbreviation

1

Naphthalene

1-hydroxynaphthalene

1-NAP

2

Naphthalene

2-hydroxynaphthalene

2-NAP

3

Fluorene

9-hydroxyfluorene

9-FLU

4

Fluorene

2-hydroxyfluorene

2-FLU

5

Fluorene

3-hydroxyfluorene

3-FLU

6

Phenanthrene

1-hydroxyphenanthrene

1-PHE

7

Phenanthrene

2-hydroxyphenanthrene

2-PHE

8

Phenanthrene

3-hydroxyphenanthrene

3-PHE

9

Phenanthrene

4-hydroxyphenanthrene

4-PHE

10

Pyrene

1-hydroxypyrene

1-PYR

Safety Precautions

a. Reagent toxicity or carcinogenicity
Some of the reagents necessary to perform this procedure are toxic. Special care
must be taken to avoid inhalation or dermal exposure to the reagents necessary to
carry out the procedure.
b. Radioactive hazards
There are no radioactive hazards associated with this procedure.
c. Microbiological hazards
Although urine is generally regarded as less infectious than serum, the possibility of
being exposed to various microbiological hazards exists. Appropriate measures
must be taken to avoid any direct contact with the specimen (See Section 2.e.). CDC
recommends a Hepatitis B vaccination series and a baseline test for health care and
laboratory workers who are exposed to human fluids and tissues. Observe
Universal Precautions.
d. Mechanical hazards
There are only minimal mechanical hazards when performing this procedure using
standard safety practices. Laboratory analysts must read and follow the
manufacturer’s information regarding safe operation of the equipment. Avoid direct
contact with the mechanical and electronic components of the mass spectrometer
unless all power to the instrument is off. Generally, mechanical and electronic
maintenance and repair must only be performed by qualified technicians. The
autosampler and the mass spectrometer contain a number of areas which are hot
enough to cause burns. Precautions must be used when working in these areas.
e. Protective equipment
Standard safety precautions must be followed when performing this procedure,
including the use of a lab coat/disposable gown, safety glasses, appropriate gloves,
and chemical fume hood. Refer to the laboratory Chemical Hygiene Plan and CDC
Division of Laboratory Sciences safety policies and procedures for details related to
specific activities, reagents, or agents.
f. Training
Formal training in the use of a high resolution mass spectrometer is necessary.
Users are required to read the operation manuals and must demonstrate safe
techniques in performing the method. Anyone involved in sample preparation must
be trained in for all sample preparation equipment, chemical handling, and have
basic chemistry laboratory skills.
g. Personal hygiene
Follow Universal Precautions. Care must be taken when handling chemicals or any
biological specimen. Routine use of gloves and proper hand washing must be

practiced. Refer to the laboratory Chemical Hygiene Plan and CDC Division of
Laboratory Sciences safety policies and procedures for details related to specific
activities, reagents, or agents.
h. Disposal of wastes
Waste materials must be disposed of in compliance with laboratory, federal, state,
and local regulations. Solvents and reagents must always be disposed of in an
appropriate container clearly marked for waste products and temporarily stored in a
chemical fume hood. All disposable items that come in direct contact with the
biological specimens are to be placed in a biohazard autoclave bag that must be
kept in appropriate containers until sealed and autoclaved. The unshielded needles,
pipette tips and disposable syringes must be placed immediately into a sharps
container and autoclaved when this container becomes full. Wipe down all surfaces
with a freshly prepared bleach solution (a 10% dilution of commercial sodium
hypochlorite (bleach) or equivalent) when work is finished. Any non-disposable
glassware or equipment that comes in contact with biological samples must be
washed with bleach solution before reuse or disposal. Any other non-disposable
glassware must be washed and recycled or disposed in an appropriate manner.
Observe Universal Precautions. Dispose of all biological samples and diluted
specimens in a brown glass bottle; disinfect the bio-hazardous material with bleach
(10% in final volume), and dispose according to CDC/DLS guidelines for disposal of
hazardous waste. Dispose all used disposable laboratory supplies (tubes, pipette tips,
etc.) in an autoclave bag at the end of the analysis according to CDC/DLS guidelines
for disposal of hazardous waste.
3.

Computerization; Data-System Management
a. Software and knowledge requirements
This method has been validated using the Thermo Finnigan GC/HRMS system
controlled by XcaliburTM Software 1.3. Analyte peaks are integrated by Quan
Browser under XcaliburTM. Results are exported from Quan Browser result files to
Microsoft Excel files that are subsequently used for calculations. Final results are
stored in Excel format. Knowledge of and experience with these software packages
(or their equivalent) is required to utilize and maintain the data management
structure.
b. Sample information
Information pertaining to particular specimens is entered into the database either
manually or electronically transferred. The result file is transferred electronically into
the database. No personal identifiers are used, and all samples are referenced to a
blind coded sample identifier.
c. Data maintenance

All sample and analytical data are checked prior to being entered into the MS Excel
for transcription errors and overall validity. The database is routinely backed up
locally through the standard practices of the NCEH network. The local area network
manager must be contacted for emergency assistance.
d. Information security
Information security is managed at multiple levels. The information management
systems that contain the final reportable results are restricted through user ID and
password security access. The computers and instrument systems that contain the
raw and processed data files require specific knowledge of software manipulation
techniques and physical location. Site security is provided at multiple levels through
restricted access to the individual laboratories, buildings, and site. Confidentiality of
results is protected by referencing results to blind coded sample IDs (no names or
personal identifiers have used).
4.

Procedures for Collecting, Storing, and Handling Specimens; Criteria for
Specimen Rejection
a. Special instructions
No special instructions such as fasting or special diets are required.
b. Sample collection
Urine specimens are collected from subjects in standard urine collection cups.
Samples must be refrigerated as soon as possible, and must be transferred to
specimen vials within 24 hours of collection. A minimum of 5 milliliters of urine is
collected and poured into sterile vials with screw-cap tops. The specimens are then
labeled, frozen immediately to -20 ºC, and stored on dry ice for shipping. Special
care must be taken in packing to protect vials from breakage during shipment. All
samples in long-term storage must be kept at -70 ºC until analysis.
c. Sample handling
Specimen handling conditions are outlined in the Division of Laboratory Science
(DLS) protocol for urine collection and handling (copies available in branch,
laboratory and special activities specimen handling offices). Collection, transport,
and special requirements are discussed in the division protocol. In general, urine
specimens must be transported and stored at frozen (< -10 ºC). Once received, they
can be frozen at -70 ± 10 °C until time for analysis. Portions of the sample that
remain after analytical aliquots are withdrawn must be refrozen at -70 ± 10 °C.
Samples are not compromised by repeated freeze and thaw cycles.
d. Sample quantity
The minimum amount of specimen required for analysis is 0.5 mL, with the optimal
amount being 2.0 mL.
e. Unacceptable specimens

Specimens must be frozen at a minimum of -20 ± 5 °C when delivered to the lab.
The minimum volume required is 0.5 mL. If either of these criteria is violated, then
specimen must be rejected. Specimens are also rejected if suspected of
contamination due to improper collection procedures or devices. Specimen
characteristics that may compromise test results include contamination of urine by
contact with dust, dirt, etc. from improper handling. Samples with visible
microbiological growth (e.g. mold, bacteria) must also be rejected. In all cases,
request a second urine specimen if available. A description of reasons for each
rejected sample must be recorded on the sample transfer sheet, such as low sample
volume, leaking or damaged container.
5.

Procedures for Microscopic Examinations; Criteria for Rejecting Inadequately
Prepared Slides
Not applicable for this procedure.

6.

Preparation of Reagents, Calibration Materials, Control Materials, and all Other
Materials; Equipment and Instrumentation
a. Reagents and sources
See Table 2.
Table 2. Reagents and the respective manufacturers

Reagent

Manufacturers*

organic de-ionized water (D.I. H 2 O)

Prepared in house, CDC (Aqua Solutions,
Inc.)

β-glucuronidase/arylsulfatase, H-1, powder
enzyme

Sigma Chemical, St. Louis, MO

pentane, hexane, acetonitrile, toluene, and
methanol (ABSOLV grade)

Tedia Company, Fairfield, OH

glacial acetic acid

Sigma Chemical, St. Louis, MO
Fisher Scientific, Pittsburgh, PA

Silver nitrate

Fisher Scientific, Pittsburgh, PA
Sigma Chemical, St. Louis, MO

sodium acetate

Sigma Chemical, St. Louis, MO

N-methyl-N-(trimethylsilyl)trifluoroacetamide (MSTFA)

Sigma Chemical, St. Louis, MO

argon, nitrogen
13

13

Air Products and Chemicals, Allentown, PA
13

C 6 3-PHE, C 12 -PCB105, C 6 1-NAP,
C 6 2-NAP, 13C 6 9-FLU

13

Cambridge Isotope Laboratories, Andover,
MA

13

C 6 3-FLU, 13C 6 1-PYR

ChemSyn, Lenexa, KS

13

Los Alamos National Laboratory, Los
Alamos, NM

1-NAP, 2-NAP, 2-FLU, 3-FLU, 9-FLU, 1PYR

Sigma-Aldrich Chemicals, St. Louis, MO

1-PHE, 2-PHE, 3-PHE, 4-PHE

Promochem, Wesel, Germany

C 6 3-FLU, 13C 6 9-FLU, 13C 6 2-PHE

* Equivalent products from other manufacturers may be used.
b. Preparation of Reagents
1)

Sodium Acetate Buffer solution (1 M, pH 5.5)
Place 41 g sodium acetate powder in a 500-mL vitro bottle and add
approximately 300 mL de-ionized water (D.I. H 2 O). Stir on a stir plate until
sodium acetate is completely dissolved. Fill flask to the 500 mL line with D.I.
H 2 O. Adjust the pH to 5.5 with glacial acetic acid.

2)

β-glucuronidase/arylsulfatase Enzyme/Buffer solution (10 mg enzyme/mL
buffer)
Weigh 0.5 g of β-glucuronidase/arylsulfatase, H-1, powder enzyme into a 60mL ASE glass vial. Add 50 mL of the pre-prepared sodium acetate buffer and
cap the vial. Place vial on a rotating mixer at 40 rpm until the enzyme is
completely dissolved.

3)

N-methyl-N-(trimethylsilyl)-trifluoroacetamide (MSTFA)
Open the sealed vial containing MSTFA from the vendor and place the MSTFA
solution in an amber screw-cap vial (2-mL). Displace the air over the MSTFA
with a gentle stream of argon. The MSTFA can be stored in the amber screwcap vial for up to 1 month. To add MSTFA to multiple samples, use an
Eppendorf repeator pipette with a 100-µL pipette tip, set the pipette volume at
10 µL, and then withdraw 100 µL of MSTFA. Discard the first two aliquots and
the last aliquot of MSTFA (10 µL per aliquot), aliquot 10 µL into each of the
sample vials.

c. Preparation of Calibration Materials
All standard preparations are based on gravimetric determination, not by volume.
Therefore, the final actual concentrations have minor deviation from the target
concentrations, e.g. target concentration for an individual stock solution is 100
ng/uL; the actual concentration is 98.7 ng/uL. Actual calculated concentrations
based on weight are used in all data calculation and processing.
All OH-PAH are light sensitive and precautions to minimize exposure to light must
be taken, such as use of UV-filtered yellow light in lab areas where samples are
handled.

1)

Stock Solutions of Individual Analytes (target concentrations: 100 ng/µL, 400
ng/µL for 1- and 2-NAP)
Approximately 5-10 mg of neat standard is weighed into a silanized screw cap
amber vial. Add 3 mL of acetonitrile into the vial and record the exact weight of
the solvent. Allow the OH-PAH to dissolve by gentle swirling or placing in an
ultrasonic bath. Dilute the individual standards using toluene to 100 ng/µL (400
ng/µL for 1- and 2-NAP) with a final volume of 3.0 mL. All solutions are stored
in a refrigerator with an inert argon atmosphere in the vials.

2)

Working Standard Solution of 10 native OH-PAH mix (W.S.A)
Combine 400 µL from each of the individual native OH-PAH standard stock
solutions in a silanized screw cap amber vial to generate the working standard
solution (W.S.A, target concentration at 4 ng/µL for each native OH-PAH
concentration, except for 1- and 2-NAP at 16 ng/µL). Homogenize the mixture
by gentle swirling and vortexing. Solutions of other concentrations may also be
prepared, if needed. Displace air in the vial with argon, cap the vials, and
stored them in a refrigerator until needed.

3)

Working Standard Solution of 10 C13-labeled OH-PAH mix (W.S.I)
Combine individual 13C-labeled OH-PAH standard stock solutions (90 ng/µL) in
a silanized screw cap amber vial to generate the working internal standard
solution (W.S.I, target concentration at 6 ng/µL for each of the 10 13C-labeled
OH-PAHs, except for C13-labeled 1- and 2-NAP at 24 ng/µL). Homogenize the
mixture by gentle swirling and vortexing. Displace air in the vial with argon, cap
the vials, and stored them in a refrigerator until needed.

4)

External Calibration Standards (E.C.S)
External calibration standards (E.C.S.) are prepared as presented in Table 3
below. Concentrations for 1- and 2-NAP in all standards are 4 times higher than
the rest of the native compounds, because these two compounds are present
in urine samples at high concentrations. Target concentrations for 13C-labled
internal standards are 100 pg/µL (400 pg/µL for C13-labeled 1- and 2-NAP) in
all calibration standards.
In addition, due to high concentrations for 1- and 2-NAP often found in
specimens, two additional calibration standards were prepared. The two
calibration standards are at levels of 2000 and 4000 pg/µL (8000 and 16,000
pg/µL for 1- and 2-NAP), and were used to evaluate and extend the linear
range of the instrument calibration curves.
Table 3. Preparation of external calibration standards (ECS)

Standard
No.
1

5)

Analytes, excluding 1- & 2-NAP
Target
Equivalent
concentration concentration in
(pg/µL)
urine(pg/mL)
1
5

1- and 2- NAP
Target
Equivalent
concentration concentration in
urine (pg/mL)
(pg/µL)
4

20

2

2

10

8

40

3

5

25

20

100

4

10

50

40

200

5

50

250

200

1,000

6

100

500

400

2,000

7

500

2500

2,000

10,000

8

1000

5,000

4,000

20,000

Internal Qualification Standards (I.Q.S)
Weigh in 4.167 mL of W.S.I into a 1-L silanized volumetric flask. Dilute the
solution with acetonitrile to the 1-L line to get the internal qualification standard
(I.Q.S). The target concentration of each 13C-labeled OH-PAH is 25 pg/µL.
Aliquot 1.9 mL of I.Q.S. into amber 2-mL standard vials, cap and seal the vials
with Argon. Store all I.Q.S. vials in the fridge until use.

6)

Mass Spectrometric Check Solution
This solution is used daily to monitor the operating performance of the GC
column and the mass spectrometer. A solution of 20 fg/µL of a tetrachlorinated dioxin is used as the check solution. For a 1 µL injection, a
minimum signal-to-noise of 4 on the m/z 321.894 peak must be obtained.

d. Preparation of Control Materials
1)

Quality Control (QC) materials
Prepare quality control materials by spiking a known amount of native OH-PAH
mixture (in acentonitrile) into 2000 mL of an anonymous filtered urine pool (500
pg/mL urine). Homogenize the QC solutions overnight for equilibration. On the
next day aliquot the QC solutions into 16 x 100 mm test tubes (2 mL in each
tube) and store them at -70 ± 10 °C until use.

2)

Recovery Spiking Solution (R.S.S)
The recovery standard (13C 12 PCB105) was purchased as a solution (40
µg/mL, in nonane). Dilute the standard solution using toluene to 100 pg/µL.
This will be used as the recovery spiking solution (R.S.S.). Aliquot 1.7 mL of
E.R.S. into amber 2-mL standard vials, cap and seal the vials with Argon. Store
all E.R.S. vials at 4 ± 5 °C until use.

3)

Proficiency Test Material (PT)
Prepare quality control materials by spiking a known amount of W.S.A (at a
different level as the QC) into 100 mL of an anonymous urine pool (filtered) to
achieve the target concentration. Prepare four urine pools at levels within the
linear range of the method. After spiking the urine pool with a known amount of
W.S.A, homogenize the PT solutions overnight for equilibration. On the next
day aliquot the PT solutions into 16 x 100 mm test tubes (2 mL in each tube),
the PT samples were then randomized by an external PT administrator, labeled
by external lab technicians, and store them at -70 ± 10 °C until use.

e. Other equipment, materials, and supplies
Materials / supplies and sources used during the development, validation, and
application of this method are listed below. Materials / supplies procured from other
sources must meet or exceed these specifications.
•

Gilson 215 liquid handler (Gilson Inc., Middleton, WI)

•

818 Automix mixer (Gilson Inc., Middleton, WI)

•

Water bath/sonicator (Branson Ultrasonics, Danbury, CT)

•

TurboVap LV evaporator (Caliper LifeSciences, Hopkinton, MA)

•

Incubator ovens (Fisher Scientific)

•

pH meter (Thermo)

•

Microbalance (Mettler-Toledo)

•

Stirring/heating plates (Corning)

•

Miscellaneous glassware (Pyrex, Kimax, Wheaton or Corning)

•

Eppendorf Repeater Plus Pipette (Brinkmann Instruments Inc., Westbury,
NY).

•

Rainin Electronic Pipettes (Rainin, California)

•

Pasteur pipettes and bulbs (VWR).

•

Maxi-mix Vortex mixer (Barnstead International)

•

Allegra-6 centrifuge (Beckman-Coulter)

•

Amber screw top vials with various volume (Supelco, Inc., Bellefonte, PA)

•

Clear autosampler vials, 0.5 mL (SunSri)

f. Instrumentation
The analyses are performed on a ThermoFinnigan MAT-95XL high resolution mass
spectrometer (Finnigan MAT, San Jose, CA) equipped with an electron impact

ionization and interfaced to an Agilent Technologies 6890 gas chromatograph (GC)
system (Agilent Technologies, Palo Alto, CA)
1)

Gas chromatograph configuration
Chromatographic separation is performed on an Agilent 6890 gas
chromatograph fitted with a DB-5 30-m fused silica capillary column. The
column ID is 0.25-mm and the film thickness is 0.25-micron (J&W, # 22-5022 or
equivalent). The temperature program lasts a total of 28 minutes. (See Table 4
for GC configuration and Table 5 for the GC temperature program.)
Table 4. GC configuration
GC Parameter

Setting

Carrier gas

Helium

Constant flow rate

1 mL/minute

GC purge flow rate

70 mL/minute

GC saver time

5 minutes

GC save flow rate

15 mL/minute

Injection mode

Splitless

Injector purge delay

2 minutes

Injector temperature

270 ºC

Table 5. Typical GC temperature program. Slight modification might be
required to accommodate separation variations on commercial GC
columns.

2)

Time
(min.)

Ramp
(C/min)

Temperature (ºC)

0

0

95

2

15

95

6

5

155

20

40

225

22.4

0

320

27.4

-

320

High Resolution Mass spectrometer (HRMS) configuration

Thermo Finnigan MAT 95XL HRMS configuration is presented in Table 6. The
mass spectrometer is operated under Multiple Ion Detection (MID) mode. The
masses used to quantify analytes are presented in Table 7.
Table 6. Thermo Finnigan MAT 95XL HRMS configuration
HRMS Parameter

Setting

Scan mode

Multiple ion detection

Ionization type

Electron impact

Ion polarity mode

Positive

Electron energy

45 eV

Resolution

10,000

Ion source

250 ºC

Conversion dynode voltage

Positive

Electron multiplier voltage

1.45 – 2.25 kV (or 106 gain)

Table 7. Analyte masses
Analyte
1-NAP, 2-NAP

216.0970

2-FLU, 3-FLU, 9-FLU

254.1127

1-PHE, 2-PHE, 3-PHE, 4-PHE

266.1127

1-PYR

290.1127

13

222.1172

13

260.1328

13

270.1263

13

272.1328

13

272.1328

C 6 1-NAP, 13C 6 1-NAP
C 6 2-FLU, 13C 6 3-FLU, 13C 6 9-FLU
C 4 4-PHE, 13C 4 1-PHE
C 6 3-PHE, 13C 6 2-PHE
C 6 1-PYR

7.

Molecular Ion
[M.+]

Calibration and Calibration Verification
a. Calibration of Mass Spectrometer
Calibrate and tune the Finnigan MAT 95XL mass spectrometer using FC43
(perfluorotributylamine) according to the instructions in the operator’s manual
located next to the instrument. After calibrated with 10,000 resolution and maximum

sensitivity, the instrument is prepared for the analysis of OH-PAHs as described in
Section 8.
b. Creation of calibration curve
1)

Calculation data
A linear log-log calibration curve, using eight ECS with concentration ranging
from 1 to 1000 pg/µL, is generated using the log ratio of the peak area of the
analyte to the labeled internal standard against the log ratio of the native
analyte concentrations to those of the labeled internal standards. The
concentrations in ECS correspond to 5 - 5,000 pg/mL (20-20,000 pg/mL) levels
in 2 mL urine. For urine samples with concentrations higher than the
calibration curve, the highest two standards (2000 & 4000 pg/ µL, 8,000 and
16,000 pg/µL for 1-&2-NAP) are prepared to extend the calibration curve and to
accurately quantify those samples.

2)

Evaluation of curve statistics
The R-squared value of the curve must be equal to or greater than 0.990.
Linearity of the standard curve must extend over the entire standard range.

3)

Use of the calibration curve
The lowest point on the calibration curve is the lowest reportable level and the
highest point is above the expected range of results. The remainders of the
points are distributed between these two extremes, with the majority of points in
the concentration range where most unknowns fall.

c. Calibration verification
In order to verify that this calibration of this test system is accurate and stable
throughout reportable range, a full calibration curve is run monthly. Calculated
concentration must be within 10% deviation from expected concentration.

8.

Procedure Operation Instructions; Calculations; Interpretation of Results
An analytical run consists of two blanks, two QCs, and 16 unknown urine samples.
a. Sample Preparation
All samples are prepared in a laboratory with non-UV yellow fluorescent lights.
1)

Hydrolysis
Allow urine samples and QCs to thaw and reach room temperature. Aliquot 2
mL of urine sample (or 2 mL of D.I. H 2 O as blank) into a 16x100 mm test tube.
Add 1 mL of 1 M sodium acetate butter (pH = 5.5) containing β-Glucuronidase/

arylsulfatase enzyme from Helix pomatia (10 mg enzyme/1 mL buffer) into the
test tube. Place the uncapped sample tubes on the Gilson 215 liquid handler
(Gilson Inc., Middleton, WI) initiate the automated spiking procedure. All
samples are spiked with 40 µL of I.Q.S on the Gilson 215 liquid handler. Cap
the test tubes and invert gently several times to mix well. Place the samples in
a 37 ± 2 ºC oven and incubate the sample overnight (~17-18 hours).
2)

Automated Liquid-Liquid Extraction
Add D.I. water (2 mL) to all samples prior to using the Gilson 215 liquid handler
(Gilson Inc., Middleton, WI) fitted with an 818 AutoMix for automation. Place the
uncapped sample tubes in the Gilson 215 and initiate the extraction procedure.
The automated procedure will add 20% toluene/80% pentane (5 mL) to each
sample. Manually cap the tubes then place back on the AutoMix to mix for 5
minutes (20 rpm). Centrifuge samples at 2800 rpm on an AllegraTM 6
centrifuge (Beckman Coulter Inc., Fullerton, CA) until clear separation can be
seen between layers (~20-40 minutes). Uncap the tubes and return them to the
Gilson 215 to resume automation. The liquid handler probe will transfer the
organic phase to clean 16x100 test tubes. Repeat extraction a second time
until a total of 10mL of organic phase is collected in each test tube. The urine
sample test tubes are no longer needed and may be discarded.

3)

Evaporation
Spike the extract with 10 µL dodecane and place in a TurboVap LV evaporator.
Under a stream of N 2 and in a 40 ºC water bath, evaporate the pentane fraction
(~10-15 minutes). Transfer the remaining extract volume (~2mL) to a second
TurboVap LV evaporator warmed with an 80 ºC water bath. Evaporate extracts
to ~10µL within 20-30 minutes. Spike each sample tube with 20 µL toluene
and 5 µL R.S.S., vortex for a few seconds, and then transfer the contents to an
amber autosampler vial.

4)

Derivatization
Add 10 µL of MSTFA into the GC vial and then displace the air in the vial with a
gentle stream of argon. Quickly screw a cap onto the vial. Place the vials in an
incubator or oven set at 60 ± 5 ºC for 30 minutes. The samples are then ready
for analysis on the mass spectrometer.

b. Instrument and software setup for the GC/HRMS
1)

Preliminary MAT 95 system setup and performance check
Turn on the MAT 95; inject 2 µL FC-43 into the reference inlet. In the TUNE
window, adjust resolution between 9900 and 10100. Perform a GC/HRMS
analysis of the mass spectrometer check solution (2, 3, 7, 8-TCDD, 10 fg/µL,
1 µL injection) and verify chromatographic resolution and peak intensity. In the
lab note book, record the signal to noise of the check compound.

2)

Final setup and operation
a) Create the run sequence
In the Xcalibur Sequence Setup window, create a sequence for the run
using the template. Make sure that the appropriate number of samples is
loaded, the appropriate filenames are assigned, and the appropriate sample
positions on the autosampler tray are included in the run sequence. Make
sure that the correct process method and instrument method are selected.
The latter defines GC, MID, Autosampler, and ICL methods. The methods
used are listed in Table 8.
Table 8. GC/HRMS methods
Program

Method

Instrument

NHANES.met

GC

NHANES.mcr

MID

NHANES.mid

Autosampler

pah_1ul.mcs

ICL

Sleep90.icl 7

Process

NHANES.pmd

Filenames conform to the following format: PMYYNNN, KMYYNNN or
JMYYNNN where P = PAH samples run on the MAT 95 instrument named
as CASSI, K = PAH samples run on the MAT 95 instrument named as
MIKE, J = PAH samples run on the MAT 95 instrument named as ICE; M =
month (A = January, B = February, C = March, etc.); YY = year (04 = year
2004), and NNN = run number for the month. For example, the filename
PB01012 corresponds to PAH-February-2001-sample #12 run on MAT 95 –
CASSI, and KD02267 would correspond to PAH-April-2002-sample #267
run on MAT 95 – MIKE.
b) Start the sequence
Click Run Sequence in the main menu under Action. Verify the sequence
set up and make sure the whole sequence instead of one single sample is
selected to be run. Click OK; the system will immediately start by turning
green on the first sample to run.
3)

System standby
To place the MAT 95 in standby mode, enter the command .bye at the ICL
prompt. This command turns off the accelerator, multiplier and dynode voltage,
and vents the reference compound (FC-43). To reactivate the MAT 95, enter
.run 0.50 at the command prompt. Add the reference compound and tune.

c. Processing of data
After the run sequence finishes, process all raw data files in the whole sequence
using the “NHANES.pmd” process method after which the analyte peaks in data files
are automatically integrated using the process method. Visually review and
manually correct if needed the integration of each peak in the QuanBrowser window
of the Xcalibur software. Save the reviewed result file, export it as a MS Excel file,
and save the Excel file on the Q:\ share drive. Perform all further calculations such
as standard curve generation, QC analysis, blank analysis, limit-of-detection
determination, unknown sample calculations, data distribution, etc. in MS Excel and
in SAS. Import final results and all supporting information into a RBase database
located on the Q:\ share drive.
d. Replacement and Periodic Maintenance of Key Components
1)

MAT 95 XL Mass Spectrometer
Check cooling water level and temperature monthly
Clean the ion volume or replace it monthly
Clean the ion source or replace it annually
Replace the calibration gas septum monthly
Trained Thermo Finnigan technicians perform all other maintenance based on
an annual schedule, or as needed

2)

Agilent 6890 GC
Change the injection port liner and septum daily
Clean the injection port, clean or replace the gold seal monthly
Cut the GC column for ~10” monthly or as needed
Replace the GC column at 1000 analyses or sooner
Replace Helium tank when the pressure is below 500 psi.
Note: Accelerate the above maintenance schedules if necessary.

9.

Reportable Range of Results
The linear range of the standard calibration curves determines the highest and lowest
analytical values of an analyte that are reportable. The calibration verification of the
method encompasses this reportable range. However, urine samples with analytical
data values exceeding the highest reportable limit may be re-extracted using a smaller
volume and re-analyzed so that the result is in the reportable range.
a. Linearity Limits
Analytical standards were linear for all analytes through the range of concentrations
evaluated. The linear range for all analytes except 1-NAP and 2-NAP is 5 pg/mL to
40,000 pg/mL. Calibration curves for 1-NAP and 2-NAP are extended to 160,000
ng/L, because their high concentrations detected from unknown samples.
Therefore, the linear range for 1-NAP and 2-NAP were 20 pg/mL to 160,000 pg/mL.

Urine samples whose concentrations exceed these ranges must be diluted and reanalyzed using a smaller aliquot.
b. Limit of Detection
The limit of detection (LOD) for this method is defined as the greater LOD calculated
by two methods: (i) in direct relation to method blanks prepared in parallel with the
unknown samples, as 3 times the standard deviation of the method blanks, and (ii)
according to the instrumental detection limit defined as the lowest point in the
calibration curve (1 pg/uL, or 5 pg/mL in 2-mL urine samples) verified to give a signal
with the S/N equal to or greater than 5. The detection limits determined for each
analyte are evaluated periodically (e.g. every 6 months or after an NHANES cycle)
based on observed blank levels over the period. Typical LODs are presented in
Table 9 (updated after NHANES 2005-06).
Table 9. Limits of detection (LOD)

Analyte
1-NAP
2-NAP

LOD (pg/mL)
48
13

9-FLU
3-FLU

5
5

2-FLU

5

4-PHE
3-PHE

5
5

1-PHE
2-PHE

5
5

1-PYR

5

c. Precision
The precision of the method is reflected in the variance of quality control samples
analyzed over time. The mean and coefficients of variation (CV) of the 318 QC
samples over the analysis of NHANES 2005-06 are listed in Table 10 below. These
QC samples were prepared over 6 months by two different analysts using two
automated liquid handlers and two GC/HRMS instruments.
Table 10. Mean, standard deviation, and CV for QC samples. The parameters are QC
pool specific.

Analyte
1-NAP
2-NAP
9-FLU
3-FLU

Mean (pg/mL)

Stdev (pg/mL)

CV (%)

519
791
539
433

33
28
12
10

6.4%
3.5%
2.1%
2.3%

2-FLU
4-PHE
3-PHE
1-PHE
2-PHE
1-PYR

507
508
501
339
493
485

12
16
13
10
12
17

2.4%
3.1%
2.6%
2.8%
2.5%
3.6%

d. Analytical specificity
The HRMS system provides excellent analytical specificity. The analyte peaks are
located in well defined regions of the chromatogram with no visible interferences and
low background. In addition, the retention time for the analytes relative to the
isotope internal standards give additional confirmation of the presence of analytes in
the sample.
e. Accuracy
Presently no established standard reference material (SRM) exists for OH-PAHs in
human urine. Therefore, we cannot evaluate the accuracy of this method by
analyzing an SRM and compare to its certified concentrations. Nonetheless, the
usage of isotopically labeled internal standards can adjust for any deviates occurred
on the OH-PAH analytes during sample preparation and instrumental analysis, and
thus provide assurance on the accuracy of this method.
10. Quality Assessment and Proficiency Testing
a. Quality Assessment
Quality assessment procedures follow standard practices6. Daily experimental
checks are made on the stability of the analytical system. Blanks and standards, as
well as QC materials, are added to each day's run sequence. The blank and
standard are analyzed at the beginning of each run to check the system for possible
contamination or in the spiking solutions and/or reagents. Two QCs are prepared
and analyzed with each run; their concentrations are compared with acceptance
criteria to assure the proper operation of the analysis. Relative retention times are
examined for the internal standard to ensure the choice of the correct
chromatographic peak.
b. Quality Control Procedures
1)

Establishing QC limits
Quality control limits are established by characterizing assay precision with
repetitive analyses of the QC pool. Different variables are included in the
analysis (e.g. different analysts and instruments) to capture realistic assay
variation over time. The mean, standard deviation, coefficient of variation, and
confidence limits are calculated from this QC characterization data set.
Individual quality control charts for the characterization runs are created,

examined, and quality control limits are used to verify assay precision and
accuracy on a daily basis. QC characterization statistics for OH-PAH analytes
in NHANES 2005-06 are listed in Table 11. The characterization statistics are
pool specific.
Table 11. Sample QC Characterization Statistics. The data are QC pool specific.

2)

Analyte

Mean - 3σ
(pptr)

Mean - 2σ
(pptr)

Mean
(pptr)

1-NAP

420

453

519

585

618

2-NAP

707

735

791

847

875

9-FLU

503

515

539

563

575

3-FLU

403

413

433

453

463

2-FLU

471

483

507

531

543

4-PHE

460

476

508

540

556

3-PHE

462

475

501

527

540

1-PHE

309

319

339

359

369

2-PHE

457

469

493

517

529

1-PYR

434

451

485

519

536

Mean + 2σ Mean + 3σ
(pptr)
(pptr)

Quality Control evaluation
After the completion of a run, the quality control limits are consulted to
determine if the run is “in control”. The quality control rules apply to the
average of the beginning and ending analyses of each of the QC pools. The
quality control results are evaluated according to Westgard rules:
If both of the QCs are within the 2σ limits, then accept the run.
If one of two QC results is outside the 2σ limits, then apply the rules below and
reject the run if any condition is met.
Extreme outliner: the result is outside the characterization mean by more than
4σ limit.
1 3σ – Average of both QCs is outside of a 3σ limit.
2 2σ –QC results from two consecutive runs are outside of 2σ limit on the same
side of the mean.
R 4σ sequential –QC results from two consecutive runs are outside of 2σ limit
on opposite sides of the mean.
10 x sequential – QC results from ten consecutive runs are on the same side of
the mean.
If the QC result for an analyte is declared “out of control”, the results of that
analyte for all patient samples analyzed during that run are invalid for reporting.

c. Proficiency Testing (PT)
1)

Scope of PT
There are no established PT materials; currently we are the only laboratory
running this essay. Therefore, the proficiency testing (PT) scheme for this
method is administered by an in-house PT coordinator. Because no standard
reference materials exist for urinary analysis of hydroxy-PAH levels, PT
samples are prepared in-house by spiking a known amount of standard into a
well characterized urine pool, and blink-coded by in-house PT coordinator.

2)

Frequency of PT
Five samples of unknown PT concentrations are analyzed twice a year using
the same method described for unknown samples. The PT administrator will
randomly select five of the PT materials for analysis. A passing score is
obtained if at least four of the five samples fall within the prescribed limits
established beforehand.

3)

Documentation of PT
Analytical PT results are reviewed by the analyst and laboratory supervisor,
and then submitted to the in-house PT Coordinator. The PT results are
evaluated by the PT Coordinator; the analysis passes proficiency testing if at
least four of the five sample results deviate < 20% from the known value. All
proficiency results shall be appropriately documented. If the assay fails
proficiency testing then the sample preparation and instrumentation are
thoroughly examined to identify and correct the source of assay error.

11. Remedial Action if Calibration or QC Systems Fail to Meet Acceptable Criteria
If the calibration or QC systems fail to meet acceptable criteria, suspend all operations
until the source or cause of failure is identified and corrected. If the source of failure is
easily identifiable, for instance, failure of the mass spectrometer or a pipetting error, the
problem is immediately corrected. Otherwise, prepare fresh reagents and clean the
mass spectrometer system. Before beginning another analytical run, re-analyze several
QC materials (in the case of QC failure) or calibration standards (in the case of
calibration failure). After re-establishing calibration or quality control, resume analytical
runs. Document the QC failures, reviewed the cases with supervisor to determine
source(s) of problem, and take measures to prevent re-occurrence of the same
problem.
12. Limitations of Method, Interfering Substances and Conditions
This method is an isotope dilution mass spectrometry method, widely regarded as the
definitive method for the measurement of organic toxicants in human body fluids. By
using high resolution mass spectrometry, most interference is eliminated. Due to the
matrix used in this procedure, occasional unknown interfering substances have been
encountered. If chromatographic interference with the internal standards occurs, reject

that analysis. If repeat analysis still results in an interference with the internal standard,
the results for that analyte are not reportable.
13. Reference Ranges (Normal Values)
Population-based reference ranges were determined from a subset of National Health
and Nutritional Survey (NHANES) 2003-2004 urine samples. The reference values are
presented in Table 12.
Table 12. Reference values from NHANES 2003-2004

Analyte
1-NAP
2-NAP
2-FLU
3-FLU
9-FLU
1-PHE
2-PHE
3-PHE
4-PHE
1-PYR

50th
2260
2960
280
103
269
166
62.2
118
25.9
91.3

Reference range concentrations
Fresh weight (ng/L)
Creatinine adjusted (ng/g crea)
th
th
th
75
90
95
50th
75th
90th
95th
7660
18500 26100
2100 6560 15100
21800
7500
17300 25800
2560 6340 14100
19900
679
1850
2670
221
495
1510
2070
302
1090
1740
86.6
256
856
1330
541
929
1390
233
412
729
1100
287
464
625
141
222
352
487
117
206
291
52.3
85.8
150
212
219
424
647
99.5
172
321
497
53.7
96.8
152
189
389
569
79.9
149
279
424

14. Critical Call Results (“Panic Values”)
It is unlikely that any result would be a "critical call", which would only be observed in
acute poisonings. There are no established “critical call” values. Application of this
method to NHANES studies will assist in determining levels of OH-PAH normally found
in healthy US populations. Test results in this laboratory are reported in support of
epidemiological studies, not clinical assessments. Data will help determine critical
exposures.
15. Specimen Storage and Handling During Testing
Urine specimens may reach and maintain ambient temperature during analysis. The
urine extracts are stored in GC vials in a -70 ºC freezer after analysis. Current studies
indicate (CDC data) that the extracts are stable for three weeks.
16. Alternate Methods for Performing Test or Storing Specimens if Test System Fails
Alternate validated methods have not been evaluated for measuring OH-PAH in urine.
If the analytical system fails, then samples must be refrigerated (at 4 ± 3 oC) until the
analytical system is restored to functionality. If long-term interruption (greater that 4
weeks) is anticipated, then store urine specimens at -70 ± 10 oC.

The method is designed to run on a GC/HRMS instrument, and is not generally
transferable to other instrumentation. If the system fails, then samples must be
refrigerated (at 4 ± 3 oC) until the analytical system is restored to functionality. If longterm interruption (greater that 4 weeks) is anticipated, then store urine specimens at -70
± 10 oC. Sample extracts in GC vials may be refrigerated for as long as three weeks. If
long-term interruption is anticipated, store sample extracts at -70 ± 10 oC.
17. Test Result Reporting System; Protocol for Reporting Critical Calls (if Applicable)
Study subject data is reported in both concentration units (ng/L) and adjusted based on
creatinine excretion (µg/g creatinine).
Once the validity of the data is established by the QC/QA system outlined above, these
results are verified by a DLS statistician, and the data reported in both hard copy and
electronic copy. This data, a cover letter, and a table of method specifications and
reference range values will be routed through the appropriate channels for approval (i.e.
supervisor, branch chief, division director) as outlined in the DLS policy and procedure
manual. After approval at the division level, the report will be sent to the contact person
who requested the analyses.
18. Transfer or Referral of Specimens; Procedures for Specimen Accountability and
Tracking
If greater than 1 mL of sample remains following successful completion of analysis, this
material must be returned to storage at -70 ± 10 °C in case reanalysis is required.
These samples shall be retained until valid results have been obtained and reported
and sufficient time has passed for review of the results.
Standard record keeping (e.g., database, notebooks, and data files) is used to track
specimens. Specimens will only be transferred or referred to other DLS Branch
laboratories or, if required, to CLIA certified laboratories. Transfer is carried out through
the DLS Samples Logistic Group. Specimens may be stored at CDC specimen
handling and storage facility (CASPIR).

19.

Summary Statistics and QC Graphs
See following pages.

Summary Statistics for 1-naphthol

Lot

N

Start
Date

End
Date

Standard Coefficient of
Mean Deviation
Variation

Lot001 102 19APR11 22SEP11 1657.04

51.43

3.1

Summary Statistics for 1-phenanthrene

Lot

N

Start
Date

End
Date

Standard Coefficient of
Mean Deviation
Variation

Lot001 107 19APR11 22SEP11 356.33

11.72

3.3

Summary Statistics for 1-pyrene

Lot

N

Start
Date

End
Date

Standard Coefficient of
Mean Deviation
Variation

Lot001 106 19APR11 22SEP11 561.19

21.20

3.8

Summary Statistics for 2-fluorene

Lot

N

Start
Date

End
Date

Standard Coefficient of
Mean Deviation
Variation

Lot001 106 19APR11 22SEP11 567.74

9.33

1.6

Summary Statistics for 2-naphthol

Lot

N

Start
Date

End
Date

Standard Coefficient of
Mean Deviation
Variation

Lot001 104 19APR11 22SEP11 1744.88

52.46

3.0

Summary Statistics for 2-phenanthrene

Lot

N

Start
Date

End
Date

Standard Coefficient of
Mean Deviation
Variation

Lot001 106 19APR11 22SEP11 507.80

11.38

2.2

Summary Statistics for 3-fluorene

Lot

N

Start
Date

End
Date

Standard Coefficient of
Mean Deviation
Variation

Lot001 106 19APR11 22SEP11 472.50

8.51

1.8

Summary Statistics for 3-phenanthrene

Lot

N

Start
Date

End
Date

Standard Coefficient of
Mean Deviation
Variation

Lot001 107 19APR11 22SEP11 515.40

12.14

2.4

Summary Statistics for 9-fluorene

Lot

N

Start
Date

End
Date

Standard Coefficient of
Mean Deviation
Variation

Lot001 107 19APR11 22SEP11 633.52

10.40

1.6
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Important Information for Users
The Centers for Disease Control and Prevention (CDC) periodically refines these laboratory methods. It is the
responsibility of the user to contact the person listed on the title page of each write-up before using the analytical
method to find out whether any changes have been made and what revisions, if any, have been incorporated.

This document details the Lab Protocol for NHANES 2009–2010 data.
A tabular list of the released analytes follows:

Data File Name Variable Name
URXPO1

PAH_F

SAS Label
1-napthol(ng/L)

URXPO2

2-napthol(ng/L)

URXPO3

3-fluorene(ng/L)

URXPO4

2-fluorene(ng/L)

URXPO5

3-phenanthrene(ng/L)

URXPO6

1-phenanthrene(ng/L)

URXPO7

2-phenanthrene(ng/L)

URXP10

1-pyrene(ng/L)

URXP17

9-fluorene(ng/L)

URXP19

4-phenanthrene (ng/L)

OH-PAH in Urine
NHANES 2009-2010
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Clinical Relevance and Summary of Test Principle
a. Clinical Relevance
Polycyclic aromatic hydrocarbons (PAHs) are a class of ubiquitous environmental
contaminants formed during incomplete combustion processes. Many of them have
been identified as suspected human carcinogens (1), but threshold levels for
carcinogenicity have not been determined for most PAHs. Occupational exposure
may occur through work involving diesel fuels and coal tars such as paving and
roofing. Possible environmental exposures include smoking, diet, smog and forest
fires (2, 3). Because of potential widespread human exposure and potential risk to
health, biomonitoring of PAHs is relevant for environmental public health. Application
of this biomonitoring method to analyze samples obtained from participants in the
National Health and Nutrition Examination Survey (NHANES) will help determine
reference ranges for these chemicals in the general U.S. population, aged 6 years
and older.
b. Test Principle
The specific analytes measured in this method are monohydroxylated metabolites of
PAHs (OH-PAHs). This procedure involves enzymatic hydrolysis of
glucuronidated/sulfated OH-PAH metabolites in urine, extraction, derivatization and
analysis using isotope dilution capillary gas chromatography tandem mass
spectrometry (GC-MS/MS) (4, 5). Ion transitions specific to each analyte and
carbon-13 labeled internal standards are monitored, and the abundances of each ion
are measured. The analytes measured in this procedure are shown in Table 1.
Table 1. Analytes measured their parent compounds, and their abbreviations.

No.

Metabolite/Analyte

Parent PAH

Abbreviation

1

1-hydroxynaphthalene

Naphthalene

1-NAP

2

2-hydroxynaphthalene

Naphthalene

2-NAP

3

9-hydroxyfluorene

Fluorene

9-FLU

4

2-hydroxyfluorene

Fluorene

2-FLU

5

3-hydroxyfluorene

Fluorene

3-FLU

6

1-hydroxyphenanthrene

Phenanthrene

1-PHE

7

2-hydroxyphenanthrene

Phenanthrene

2-PHE

8

3-hydroxyphenanthrene

Phenanthrene

3-PHE

9

4-hydroxyphenanthrene

Phenanthrene

4-PHE

10

1-hydroxypyrene

Pyrene

1-PYR

OH-PAH in Urine
NHANES 2009-2010
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Safety Precautions
a. Reagent Toxicity or Carcinogenicity
Some of the reagents needed to perform this procedure are toxic. Special care must
be taken to avoid inhalation or dermal exposure to these reagents.
β-Glucuronidase is a known sensitizer. Prolonged or repeated exposure to the
sensitizer may cause allergic reactions in certain sensitive individuals.
Note: Material Safety Data Sheets (MSDS) for the chemicals and solvents used in
this procedure can be found at http://www.msdsxchange.com/english/index.cfm.
Laboratory personnel are advised to review the MSDS before using chemicals.
b. Radioactive Hazards
There are no radioactive hazards associated with this procedure.
c. Microbiological Hazards
Although urine is generally regarded as less infectious than serum, the possibility of
being exposed to various microbiological hazards exists. Appropriate measures
must be taken to avoid any direct contact with the specimen (See Section 2.e.). CDC
recommends a Hepatitis B vaccination series and a baseline test for health care and
laboratory workers who are exposed to human fluids and tissues. Observe
Universal Precautions. Also, laboratory personnel handling human fluids and tissues
are required to take the “Blood borne Pathogens Training” course offered at CDC to
insure proper compliance with CDC safe work place requirements.
d. Mechanical Hazards
There are only minimal mechanical hazards when performing this procedure using
standard safety practices. Laboratory analysts must read and follow the
manufacturer’s information regarding safe operation of the equipment. Avoid direct
contact with the mechanical and electronic components of the mass spectrometer
unless all power to the instrument is off. Generally, mechanical and electronic
maintenance and repair must only be performed by qualified technicians. The
autosampler and the mass spectrometer contain a number of areas which are hot
enough to cause burns. Precautions must be used when working in these areas.
e. Protective Equipment
Standard safety precautions must be followed when performing this procedure,
including the use of a lab coat/disposable gown, safety glasses, appropriate gloves,
and chemical fume hood. Refer to the laboratory Chemical Hygiene Plan and CDC

OH-PAH in Urine
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Division of Laboratory Sciences safety policies and procedures for details related to
specific activities, reagents, or agents.
f. Training
Formal training in the use of a GC/MS-MS is necessary. Users are required to read
the operation manuals and must demonstrate safe techniques in performing the
method. Laboratorians involved in sample preparation must be trained for all
sample preparation equipment, chemical handling, and have basic chemistry
laboratory skills.
g. Personal Hygiene
Follow Universal Precautions. Care must be taken when handling chemicals or any
biological specimen. Routine use of gloves and proper hand washing must be
practiced. Refer to the laboratory Chemical Hygiene Plan and CDC Division of
Laboratory Sciences safety policies and procedures for details related to specific
activities, reagents, or agents.
h. Disposal of Wastes
Waste materials must be disposed of in compliance with laboratory, federal, state,
and local regulations. Solvents and reagents must always be disposed of in an
appropriate container clearly marked for waste products and temporarily stored in a
chemical fume hood. All disposable items that come in direct contact with the
biological specimens are to be placed in a biohazard autoclave bag that must be
kept in appropriate containers until sealed and autoclaved. Unshielded needles,
pipette tips and disposable syringes must be placed immediately into a sharps
container and autoclaved when this container becomes full. Wipe down all surfaces
with a freshly prepared bleach solution (a 10% dilution of commercial sodium
hypochlorite (bleach) or equivalent) when work is finished. Any non-disposable
glassware or equipment that comes in contact with biological samples must be
washed with bleach solution before reuse or disposal. Any other non-disposable
glassware must be washed and recycled or disposed in an appropriate manner. To
insure proper compliance with CDC requirements, laboratory personnel are required
to take annual hazardous waste disposal training courses.
Observe Universal Precautions. Dispose of all biological samples and diluted
specimens in a brown glass bottle; disinfect the bio-hazardous material with
bleach (10% in final volume), and dispose according to CDC/DLS guidelines for
disposal of hazardous waste. Dispose all used disposable laboratory supplies
(tubes, pipette tips, etc.) in an autoclave bag at the end of the analysis
according to CDC/DLS guidelines for disposal of hazardous waste.

3.

Computerization; Data-System Management
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a. Software and Knowledge Requirements
This method has been validated using the Agilent GC/QQQ 7000 GC-MS/MS
system controlled by Agilent MassHunter WorkstationTM software. Analyte
chromatographic peaks are integrated by Quantitative Analysis under
MassHunterTM. Results are exported from MassHunter result files to Microsoft Excel
files that are subsequently used for calculations. Final results are processed using
SAS and stored in both Excel and SAS format. Knowledge of and experience with
these software packages (or their equivalent) is required to utilize and maintain the
data management structure.
b. Sample Information
Information pertaining to particular specimens is entered into the database either
manually or electronically transferred. The result file is transferred electronically into
the database. No personal identifiers are used, and all samples are referenced to a
blind coded sample identifier.
c. Data Maintenance
All sample and analytical data are checked in MS Excel and SAS for overall validity.
The database is routinely backed up locally through the standard practices of the
CDC network. The local area network manager must be contacted for emergency
assistance.
d. Information Security
Information security is managed at multiple levels. The information management
systems that contain the final reportable results are restricted through user ID and
password security access. The computers and instrument systems that contain the
raw and processed data files require specific knowledge of software manipulation
techniques and physical location. Site security is provided at multiple levels through
restricted access to the individual laboratories, buildings, and site. Confidentiality of
results is protected by referencing results to blind coded sample IDs (no names or
personal identifiers are used).
4.

Procedures for Collecting, Storing, and Handling Specimens; Criteria for
Specimen Rejection
a. Special Instructions
No special instructions such as fasting or special diets are required.
b. Sample Collection
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Urine specimens are collected from subjects in standard urine collection cups.
Samples should be refrigerated as soon as possible, and preferably transferred to
specimen vials within 24 hours of collection. If at all possible, a minimum of 5
milliliters of urine is collected and poured into sterile polypropylene or glass vials with
screw-cap tops. The specimens should be labeled, frozen at or below -20 ºC, and
stored on dry ice for shipping. Special care must be taken in packing to protect vials
from breakage during shipment. All samples in long-term storage must be kept
frozen, preferably at -70 ºC, until analysis.
c. Sample Handling
Specimen handling conditions are outlined in the Division of Laboratory Sciences
(DLS) protocol for urine collection and handling (copies available in branch,
laboratory and special activities specimen handling offices). Collection, transport,
and special requirements are discussed in the division protocol. In general, urine
specimens should be transported and stored frozen. Once received, they should be
frozen, preferably at -70 °C, until time for analysis. Portions of the sample that
remain after analytical aliquots are withdrawn must be refrozen as soon as possible
after analysis.
d. Sample Quantity
The regular sample size for analysis is 1.0 mL, and the minimum amount of
specimen required for analysis is 20 µL.
e. Unacceptable Specimens
Specimens must be frozen when delivered to the lab. The minimum volume required
is 0.2 mL. If either of these criteria is violated, then specimen would be rejected.
Specimens are also rejected if suspected of contamination due to improper
collection procedures or devices. Specimen characteristics that may compromise
test results include contamination of urine from improper handling. Samples with
visible microbiological growth (e.g. mold, bacteria) must also be rejected. In all
cases, request a second urine specimen if available. A description of reasons for
each rejected sample must be recorded on the sample transfer sheet, such as low
sample volume, leaking or damaged container.
5.

Procedures for Microscopic Examinations; Criteria for Rejecting Inadequately
Prepared Slides
Not applicable for this procedure.

6.

Preparation of Reagents, Calibration Materials, Control Materials, and all Other
Materials; Equipment and Instrumentation
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a. Reagents and Sources
See Table 2.
Table 2. Reagents and the respective manufacturers

Reagent

Manufacturers*

de-ionized water (D.I. H 2 O)

Prepared in house, CDC (Aqua
Solutions, Inc.)

β-glucuronidase/arylsulfatase (H-1,
powder enzyme), glacial acetic acid,
sodium acetate, N-methyl-N(trimethylsilyl)-trifluoroacetamide
(MSTFA)

Sigma Chemical, St. Louis, MO

pentane, hexane, acetonitrile, toluene,
and methanol (ABSOLV grade)

Tedia Company, Fairfield, OH

argon, nitrogen

Air Products and Chemicals,
Allentown, PA

13

C 6 3-PHE, 13C 12 -PCB105, 13C 6 1NAP, 13C 6 2-NAP, 13C 6 9-FLUO

Cambridge Isotope Laboratories,
Andover, MA

13

ChemSyn, Lenexa, KS

13

Los Alamos National Laboratory,
Los Alamos, NM

1-NAP, 2-NAP, 2-FLU, 3-FLU, 9-FLU, 1PYR

Sigma-Aldrich Chemicals, St. Louis,
MO

C 6 3-FLU, 13C 6 1-PYR
C 6 3-FLU, 13C 6 9-FLU, 13C 6 2-PHE

1-PHE, 2-PHE, 3-PHE, 4-PHE
Promochem, Wesel, Germany
* Equivalent products from other manufacturers may be used.
b. Preparation of Reagents
1)

Sodium Acetate Buffer Solution (1 M, pH 5.5)
Place 41 g sodium acetate powder in a 500-mL vitro bottle and add
approximately 300 mL de-ionized water (D.I. H 2 O). Stir on a stir plate until
sodium acetate is completely dissolved. Fill flask to the 500 mL line with D.I.
H 2 O. Adjust the pH to 5.5 with glacial acetic acid.

2)

β-glucuronidase/arylsulfatase Enzyme/Buffer solution

OH-PAH in Urine
NHANES 2009-2010

Page 7 of 38

Weigh 0.5 g of β-glucuronidase/arylsulfatase, H-1, powder enzyme into a 60mL ASE glass vial. Add 50 mL of the pre-prepared sodium acetate buffer and
cap the vial. Place vial on a rotating mixer at 40 rpm until the enzyme is
completely dissolved.
3)

Ascorbic Acid Solution
Weigh 1.25g of L-ascorbic acid into a 20mL borosilicate glass vial. Add 5.0mL
of the deionized water and cap the vial. Place vial on a rotating mixer at 40 rpm
until the solute is completely dissolved.

4)

N-methyl-N-(trimethylsilyl)-trifluoroacetamide (MSTFA)
Open the sealed vial containing MSTFA from the vendor and place the MSTFA
solution in an amber screw-cap vial (2-mL). Displace the air over the MSTFA
with a gentle stream of argon. The MSTFA can be stored in the amber screwcap vial for up to 1 month. To add MSTFA to multiple samples, use an
Eppendorf repeater pipette with a 100-µL pipette tip, set the pipette volume at
10 µL, and then withdraw 100 µL of MSTFA. Discard the first two aliquots and
the last aliquot of MSTFA (10 µL per aliquot), aliquot 10 µL into each of the
sample vials.

c. Preparation of Calibration Materials
1)

Stock Solutions of Individual Analytes (target concentration: 400 ng/µL for 1and 2-NAP, 100 ng/µL for remaining analytes)
Approximately 5-10 mg of neat standard is weighed into a silanized screw cap
amber vial. Add 3 mL of acetonitrile into the vial and record the exact weight of
the solvent. Allow the standards to dissolve by gentle swirling or placing in an
ultrasonic bath. Dilute the individual standards using toluene to 100 ng/µL (400
ng/µL for 1- and 2-NAP) with a final volume of 3.0 mL. All solutions are stored
in a refrigerator with an inert argon atmosphere in the vials.

2)

Working Standard Solution of Native Standard Mix (W.S.A)
Combine 400 µL from each of the individual native standard stock solutions in a
silicanized screw cap amber vial to generate the working standard solution
(W.S.A, target concentration: 4 ng/µL for each native compound concentration,
except for 1- and 2-NAP at 16 ng/µL). Homogenize the mixture by gentle
swirling and vortexing. Solutions of other concentrations may also be
prepared, if needed. Displace air in the vial with argon, cap the vials, and store
them in a refrigerator until needed.

3)

Working Standard Solution of

13

C-labeled Standard Mix (W.S.I)
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Combine individual 13C-labeled standard stock solutions (90 ng/µL) in a
silicanized screw cap amber vial to generate the working internal standard
solution (W.S.I, target concentration: 6 ng/µL for each of the 13C-labeled
compounds, except for 13C-labeled 1- and 2-NAP at 24 ng/µL ). Homogenize
the mixture by gentle swirling and vortexing. Displace air in the vial with argon,
cap the vials, and store them in a refrigerator until needed.
4)

External Calibration Standards (E.C.S)
A typical set of external calibration standards (E.C.S.) are prepared as
presented in Table 3 below. The preparation of standards is done by
gravimetric determination. Therefore, the exact concentration for each standard
will slightly deviate from the target concentration listed in Table 3.
Concentrations for 1- and 2-NAP in all standards are 4 times higher than the
rest of the native compounds because these two compounds are present in
urine samples at higher concentrations. Target concentrations for 13C-labeled
internal standards are 100 pg/µL (400 pg/µL for 13C-labeled 1- and 2-NAP) in
all calibration standards.
In addition, due to higher concentrations of 1- and 2-NAP often found in
specimens, two additional calibration standards are prepared for 1-NAP and 2NAP. The two calibration standards are at levels of 8000 and 16,000 pg/µL and
only contain 1- and 2-NAP. These two calibration standards are used to
evaluate and extend the linear range of the instrument calibration curves.
Table 3. Preparation of external calibration standards (ECS)
Analytes, excluding 1- & 21- and 2- NAP
NAP
Standard
Equivalent
Equivalent
Target
Target
No.
concentration
concentration concentration concentration
in urine
in urine
(pg/μL)
(pg/μL)
(pg/mL)
(pg/mL)
1
1
10
40
4
2
2
20
80
8
3

5

50

20

200

4

10

100

40

400

5

50

500

200

2,000

6

100

1000

400

4,000

7

500

5000

2,000

20,000

8

1000

10,000

4,000

40,000

9

n/a

n/a

8,000

80,000
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n/a

n/a

16,000

160,000

Internal Qualification Standards (I.Q.S)
Weigh in 4.167 mL of W.S.I into a 1-L silanized volumetric flask. Dilute the
solution with acetonitrile to the 1-L line to get the internal qualification standard
(I.Q.S). The concentration of each 13C-labeled IS 25 pg/µL. Aliquot 1.9 mL of
I.Q.S. into amber 2-mL standard vials, cap and seal the vials with argon. Store
all I.Q.S. vials in the fridge until use.

d. Preparation of Control Materials
Quality Control (QC) Materials

1)

Prepare quality control materials by spiking a known amount of native standard
mixture (in acetonitrile) into 2000 mL of an anonymous filtered urine pool (300
pg/mL for QCL, 800 pg/mL for QCH). Homogenize the QC solutions overnight
for equilibration. On the next day aliquot the QC solutions into 16 x 100 mm
test tubes and store them at -70 °C until use.
2)

Recovery Spiking Solution (R.S.S)
The recovery standard (13C 12 PCB105) was purchased as a solution (40
µg/mL, in nonane). Dilute the standard solution using toluene to 100 pg/µL.
This will be used as the recovery spiking solution (R.S.S.). Aliquot 1.7 mL of
E.R.S. into amber 2-mL standard vials, cap and seal the vials with argon. Store
all E.R.S. vials at 4 °C until use.

3)

Proficiency Test Material (PT)
Prepare quality control materials by spiking a known amount of W.S.A (at a
different level as the QC) into 100 mL of an anonymous urine pool (filtered) to
achieve the target concentration. Prepare four urine pools at levels within the
linear range of the method. After spiking the urine pool with a known amount of
W.S.A, homogenize the PT solutions overnight for equilibration. On the next
day aliquot the PT solutions into 16 x 100 mm test tubes (2 mL in each tube).
PT samples are then randomized by an external PT administrator, labeled by
external lab technicians, and stored at -70 °C until use.

e. Other Equipment, Materials, and Supplies
Materials / supplies and sources, or their equivalent, used during the development,
validation, and application of this method are listed below.
•

Gilson 215 liquid handler (Gilson Inc., Middleton, WI)
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•

818 Automix mixer (Gilson Inc., Middleton, WI)

•

Water bath/sonicator (Branson Ultrasonics, Danbury, CT)

•

RapidVap evaporator (Labconco, Kansas City, MO)

•

Incubator ovens (Fisher Scientific)

•

pH meter (Thermo)

•

Microbalance (Mettler-Toledo)

•

Stirring/heating plates (Corning)

•

Miscellaneous glassware (Pyrex, Kimax, Wheaton or Corning)

•

Eppendorf Repeater Plus Pipette (Brinkmann Instruments Inc., Westbury,
NY).

•

Rainin Electronic Pipettes (Rainin, California)

•

Maxi-mix Vortex mixer (Barnstead International)

•

Allegra-6 centrifuge (Beckman-Coulter)

•

Amber screw top vials with various volume (Supelco, Inc., Bellefonte, PA)

•

Amber autosampler vials, 350 µL (National Scientific)

f. Instrumentation
The analyses are performed on an Agilent 7000A tandem mass spectrometer
(Agilent Technologies, Santa Clara, CA) equipped with an electron ionization ion
source and interfaced to an Agilent 7890A gas chromatograph (Agilent
Technologies, Santa Clara, CA).
1)

Gas Chromatograph Configuration
Chromatographic separation is performed on an Agilent 7890A GC fitted with a
ZB-5MS (Phenomenex or equivalent) 30-m fused silica capillary column. The
column ID is 0.25-mm and the film thickness is 0.25-micron. The temperature
program runs a total of 22 minutes. (See Table 4 for GC configuration and
Table 5 for a typical GC temperature program.)
Table 4. GC configuration
GC Parameter

Setting

Carrier gas

Helium

Constant flow rate

0.9 mL/min
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GC septum purge flow rate

3 mL/min

GC gas saver after

3 min

GC gas saver flow rate

20 mL/min

Injection mode

Pulsed Splitless

Injection pulse pressure

25 psi until 0.4 min

Injector temperature

270 ºC

Table 5. Typical GC temperature program. Slight modifications might be
required to accommodate separation variations on commercial GC
columns.

2)

Time (min.)

Ramp (C/min)

Temperature (ºC)

0

0

95

1.00

15

195

7.67

2

206

13.2

0

206

16.2

40

320

19.0

0

320

22.0

-

320

Tandem Mass Spectrometer (MS/MS) Configuration
The Agilent 7000A MS/MS configuration is presented in Table 6. The mass
spectrometer is operated under multiple reaction monitoring (MRM) mode. The
ion transitions used to quantify analytes are presented in Table 7.

Table 6. Thermo TSQ Quantum MS/MS configuration
MS/MS Parameter

Setting

Scan mode

Multiple reaction monitoring

Ionization type

Electron ionization
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MS/MS Parameter

Setting

Ion polarity mode

Positive

Electron energy

-70 eV

Emission current

35 µA

Ion source temperature

270 ºC

Electron multiplier voltage

operated at GAIN + 100

Table 7. Analyte MS/MS Ion Transitions.
Analyte
1-NAP
2-NAP
13
C 6 1-NAP
13
C 6 2-NAP
9-FLU
3-FLU
2-FLU
13
C 6 9-FLU
13
C 6 3-FLU
13
C 6 2-FLU
4-PHE
13
C 4 4-PHE
3-PHE
2-PHE
1-PHE
13
C 6 3-PHE
13
C 6 2-PHE
13
C 4 1-PHE
1-PYR
13
C 6 1-PYR

7.

Ion transition
216.1 → 185.1
222.1 → 191.2
254.1 → 165.0

260.1 → 170.9
234.8 → 220.0
270.1 → 238.8
266.1 → 235.2
272.1 → 241.3
270.1 → 239.3
290.1 → 258.9
296.1 → 265.2

CE (eV)
27
27
27
27
23
20
20
23
30
30
30
30
27
27
27
27
27
27
30
30

Calibration and Calibration Verification
a. Tuning and Calibration of Mass Spectrometer
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The Agilent 7000A GC-MS/MS should be tuned before each analytical run. Under
the Instrument menu in the MassHunter Workstation Software Data Acquisition
window, select “MS Tune” to open the tune window. Select the “Autotune” tab and
then the “Autotune” tab again in the lower view. Select “EI high sensitivity autotune”
from the options and “Print Autotune report” if desired, then click the “Autotune”
button. Once the autotune is complete and saved, review the results either by
printout (if that option was selected) or by the PDF that was auto-generated by the
software. The abundance of m/z 69 should be >1,000,000, and the isotope ratio of
m/z 70 to m/z 69 should be roughly 1%. The relative abundance of m/z 502 to m/z
69 should be >2.5%, and the isotope ratio of m/z 503 to m/z 502 should be roughly
10%. The repeller voltage should be <16 V. The EMV (Gain) should be < 2000 V
and gain factor >200. If these values are not met, proceed to clean the ion source or
perform other maintenance as needed.
b. Creation of Calibration Curve
1)

Calibration data
A full calibration curve is analyzed with every analytical run. A linear log-log
calibration curve, using eight ECS with concentrations ranging from 1 to 1000
pg/µL (4 to 4,000 pg/µL for 1- and 2-NAP), is generated using the log ratio of
the analyte peak area to the labeled internal standard peak area against the log
ratio of the native analyte concentrations to those of the labeled internal
standards. The concentrations in ECS correspond to 10 - 10,000 pg/mL urine
for all analytes except for 1- and 2-NAP, and 40-40,000 pg/mL urine for 1-NAP
and 2-NAP. For urine samples with concentrations higher than the calibration
curve, the highest two standards for 1- & 2-NAP are prepared to extend the
calibration curve and to accurately quantify those samples up to 160,000 pg/mL
urine.

2)

Evaluation of Curve Statistics
The R-squared value of the curve must be equal to or greater than 0.98.
Linearity of the standard curve must extend over the entire calibration range.

3)

Use of the Calibration Curve
The lowest point on the calibration curve is the lowest reportable level and the
highest point is the highest reportable level. The remainders of the points are
distributed between these two extremes, with the majority of points in the
concentration range where most unknowns fall. When sample results are over
the highest reportable level, the samples are repeated with up to 50 fold
dilution.

c. Calibration Verification
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1) Calibration verification is not required by the manufacturer. However, it should be
performed after any substantive changes in the method or instrumentation (e.g.,
new internal standard, change in instrumentation), which may lead to changes in
instrument response, have occurred.
2) All calibration verification runs and results shall be appropriately documented.
3) According to the updated Clinical Laboratory Improvement Amendments (CLIA)
regulations from 2003 the requirement for calibration verification is met if the test
system’s calibration procedure includes three or more levels of calibration
material, and includes a low, mid, and high value, and is performed at least once
every six months.
4) All of the conditions above are met with the calibration procedures for this
method. Therefore, no additional calibration verification is required by CLIA.
8.

Procedure Operation Instructions; Calculations; Interpretation of Results
An analytical run consists of eight calibration standards, two blanks, two QCLs, two
QCHs and 34 unknown urine samples.
a. Sample Preparation
1)

Enzyme Hydrolysis
Allow urine samples and QCs to thaw and reach room temperature. Aliquot 1
mL of urine (or 1 mL of D.I. H 2 O as blank) into a 16x100 mm test tube. Add 1
mL of 1 M sodium acetate butter (pH = 5.5) containing β-glucuronidase/
arylsulfatase enzyme from Helix pomatia (10 mg enzyme/1 mL buffer) into the
test tube. Place the uncapped sample tubes on the Gilson 215 liquid handler
(Gilson Inc., Middleton, WI) and initiate the automated spiking procedure. All
samples are spiked with 40 µL of I.Q.S on the Gilson 215 liquid handler. Cap
the test tubes and invert gently several times to mix well. Place the samples in
a 37 ºC oven and incubate the sample overnight (~17-18 hours).

2)

Automated Liquid-Liquid Extraction
Add D.I. water (3 mL) to all samples prior to using the Gilson 215 liquid handler
(Gilson Inc., Middleton, WI) fitted with an 818 AutoMix for automation. Place the
uncapped sample tubes in the Gilson 215 and initiate the extraction procedure.
The automated procedure will add 20% toluene/80% pentane (5 mL) to each
sample. Manually cap the tubes then place back on the AutoMix to mix for 5
minutes (20 rpm). Centrifuge samples at 2800 rpm on an AllegraTM 6
centrifuge (Beckman Coulter Inc., Fullerton, CA) until clear separation can be
seen between layers (20-30 minutes). Uncap the tubes and return them to the
Gilson 215 to resume automation. The liquid handler probe will transfer the
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organic phase to clean 16x100 test tubes. Repeat extraction a second time
which gives a total of approximately 9mL of organic phase collected in each
test tube. The urine sample test tubes are no longer needed and may be
discarded.
3)

Evaporation
Spike the extract with 10 µL dodecane and place in a RapidVap evaporator.
The evaporation is a two-stage process. First, the pentane fraction is
evaporated at 45 ºC, with 40% rotation speed, and 400-450 mbar vacuum (~10
minutes). Then, the sample tube is transferred to a second RapidVap, and the
toluene fraction is evaporated to a final volume of ~10uL at 80 ºC, with 50%
rotation speed, and 200-230 mbar vacuum (20-25 minutes). Spike each
sample tube with 20 µL R.S.S., vortex for a few seconds, and then transfer the
contents to an amber autosampler vial.

4)

Derivatization
Add 10 µL of MSTFA into the GC vial and then displace the air in the vial with a
gentle stream of argon. Quickly screw a cap onto the vial. Place the vials in an
incubator or oven set at 60 ºC for 30 minutes. The samples are then ready for
analysis on the mass spectrometer.

b. Instrument and software setup for the GC-MS/MS
1)

Preliminary MS/MS System Setup and Performance Check
The MS/MS tune must be verified in the MassHunter Workstation Software
Data Acquisition window either by a new Autotune procedure (described above
in 7a) or by performing a Check Tune. Under the Instrument menu, select “MS
Tune” to open the tune window. Select the “Autotune” tab and then the “Check
Tune” tab in the lower view. Select “Print Check Tune report” if desired, then
click the “Check Tune” button. The results of the check tune must all pass as
“OK” and the abundance of PFTBA (69.0) should be >1000000. If these results
are not met, the instrument is not ready for operation and maintenance
(cleaning, check for air leaks, etc) needs to be performed.

2)

Final Setup and Operation
a) Create the run sequence
The sequence may be created in two ways: in the MassHunter software or
in Microsoft Excel. The choice is left to the discretion of the analyst.
In the MassHunter Workstation Software Data Acquisition window, select
“Edit sequence” under the Sequence menu. Make sure that the appropriate
number of samples filenames, sample IDs, and sample positions are

OH-PAH in Urine
NHANES 2009-2010

Page 16 of 38

included in the run sequence. Include two solvent blanks after upper level
calibration standards. Make sure that each sequence row is labeled for
“Type” (Cal, Sample, etc.) and that all “Cal” standards have corresponding
“Level.” Ensure that the correct instrument method
(NHANES_UU_20130611.M) is selected. The latter defines GC, MS, and
autosampler methods.
If creating a sequence in a Microsoft Excel spreadsheet, make sure there
are the appropriate number of rows with correct filenames, sample IDs, vial
positions, sample types, and calibration levels (if applicable). The
information can then be copied and pasted from Excel into the appropriate
columns within the MassHunter sequence table.
Filenames conform to the following format: AGMYYNNNN or ARMYYNNNN
where AG = samples run on the MS/MS instrument named as AGIL, AR =
samples run on the MS/MS instrument named as ARCHIE; M = month (A =
January, B = February, C = March, etc.); YY = year (13 = year 2013), and
NNNN = run number for the month. For example, the filename AGB130012
corresponds to the 12th sample run in February 2013 on MS/MS instrument
AGIL.
b) Start the sequence
In the MassHunter Workstation Software Data Acquisition window, select
“Run sequence” under the Sequence menu. In the pop-up window that
appears, select “Disable Barcode for this sequence” and fill out the fields for
Operator Name and Data File Directory. Click RunSequence.
c. Processing of Data
Data is processed using the MassHunter QQQ Quantitative Analysis software. In the
software, select raw data files and batch them by analytical run (e.g. ABC-011).
Select and apply the quantitation method with the most recent calibration information
(2013-06_OH-ME_ECS71-78.quantmethod.XML) to the batch. The batch is then
analyzed and automatically integrated. Visually review, and manually correct as
needed, the integration of each peak. Save the batch and re-analyze to account for
updates to the calibration curve and calculated concentrations in samples due to
manual integrations. Export the results table as an MS Excel file, and place a copy
of this Excel file on the CDC shared network drive. Perform all further calculations
such as standard curve generation, QC analysis, blank analysis, limit-of-detection
determination, unknown sample calculations, data distribution, etc. in MS Excel and
in SAS. Import final results and all supporting information into a SAS dataset and
save it on the share drive.
d. Replacement and Periodic Maintenance of Key Components
1)

Agilent 7000A GC/MS/MS Mass Spectrometer
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•
•
•
•
2)

Clean the ion source every 4-6 weeks or sooner as needed
Replace the ion source filaments every 4 months or sooner as needed
Replenish the calibration gas every 12 months or sooner as needed
Trained Agilent technicians perform all other maintenance based on an
annual schedule, or as needed

Agilent 7890A GC
•
•
•
•

9.
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Clean the injection port and change the injection port liner and septum
biweekly or sooner as needed
Cut the GC column as needed
Replace the GC column after 2000 injections or sooner as needed
Replace Helium tank when the pressure is below 500 psi

Reportable Range of Results
The linear range of the standard calibration curves determines the highest and lowest
analytical values of an analyte that are reportable. The calibration verification of the
method encompasses this reportable range. However, urine samples with analytical
data values exceeding the highest reportable limit may be re-extracted using a smaller
volume (e.g., 0.2 mL or 5 fold dilution) and re-analyzed so that the result is in the
reportable range. For samples with extremely high values, samples can be diluted up to
50 folds (0.02 mL sample size).
a. Linearity Limits
Analytical standards are linear for all analytes through the range of concentrations
evaluated. The linear range is 40 pg/mL to 160,000 pg/mL urine for 1-NAP and 2NAP and 10 pg/mL to 20,000 pg/mL urine for the remaining analytes. Urine samples
whose OH-PAH concentrations exceed these ranges must be diluted and reanalyzed using a smaller aliquot (first use 0.2mL, and then 0.02 mL if needed).
b. Limit of Detection
The limit of detection (LOD) for each analyte is defined as the higher LOD calculated
by two methods, 1) In relation to method blanks: as three times the standard
deviation of the method blanks run over a 6-month period of time; 2) In relation to
instruments detection limit: defined as the lowest point on the calibration curve
verified to give a signal with the signal-noise-ratio (S/N) equal to or greater than 10.
The detection limits determined for each analyte are evaluated periodically (e.g.
every 6 months or after an NHANES cycle) based on observed blank levels over the
period. Typical LODs are presented in Table 8 (updated after NHANES 2011-12).
Table 8. Limits of detection (LOD)
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Analyte
1-NAP

LOD (pg/mL)
48

2-NAP

40

9-FLU

10

2-FLU

10

3-FLU

10

1-PHE

10

2-PHE

10

3-PHE

10

4-PHE

10

1-PYR

10

c. Precision
The precision of the method is reflected in the variance of quality control samples
analyzed over time. The mean and coefficients of variation (CV) of 318 QC samples
are listed in Table 9. These QC samples were prepared over 6 months by two
different analysts using two automated liquid handlers and two GC/MS/MS
instruments.
Table 9. Mean, standard deviation, and CV for QC samples. The parameters are QC
pool specific.
Low QC (n=30)

High QC (n=30)

Mean
(pg/mL)

Between Within
day SD
day SD
(pg/mL) (pg/mL)

CV

Mean
(pg/mL)

Between Within
day SD
day SD
(pg/mL) (pg/mL)

CV

1-NAP

812

55

27

6.3%

1233

111

59

8.3%

2-NAP

1807

112

65

5.6%

2273

153

102

5.9%

9-FLU

310

23

9

7.3%

628

48

24

7.1%

3-FLU

268

22

9

7.9%

689

56

28

7.6%

2-FLU

465

28

12

5.6%

789

85

31

10%

4-PHE

317

18

9

5.2%

773

42

31

4.7%

3-PHE

273

17

9

5.8%

704

40

31

4.8%

1-PHE

274

17

10

5.7%

691

45

31

5.6%

2-PHE

210

29

8

13%

596

81

25

13%

1-PYR

348

26

17

6.5%

906

71

58

6.4%

Analyte
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d. Analytical Specificity
The use of a triple-quadrupole MS allows a means of monitoring ion/mass transitions
specific to each analyte. The analyte peaks are located in well-defined regions of
the chromatogram with no visible interferences and low background. The retention
time for the analytes relative to the isotope internal standards give additional
confirmation of the presence of analytes in the sample. The relative retention time
(RRT) ratio of a native analyte against its labeled internal standard cannot deviate
more than 0.15% (OH-PAHs) from that in calibration standards.
e. Accuracy
The accuracy of this method was evaluated by analyzing two NIST Standard
Reference Materials (SRMs) and compared to its certified concentrations for the 10
OH-PAHs (Table 10).
Table 10. Measured concentrations using CDC method in comparison to the
certified concentrations in two NIST SRMs
Analyte
1-NAP
2-NAP
9-FLU
3-FLU
2-FLU
4-PHE
3-PHE
1-PHE
2-PHE
1-PYR

SRM 3672 Smoker urine
This
NIST
method
Certified* accuracy

SRM 3673 Non-smoker urine
This
NIST
method
Certified* accuracy

33868

34,400

98%

197277

211,000

93%

8768

8,730

100%

1342

1,345

100%

357

337

106%

109

110

99%

404

428

94%

35

39

90%

823

870

95%

94

107

88%

36

49

74%

8

10

77%

97

125

78%

20

28

70%

141

136

103%

50

49

102%

89

84

106%

23

25

94%

201

173

116%

32

30

106%

* Certified concentrations on OH-PAHs were obtained from the SRMs’ draft Certificate of Analysis
(COAs, internal communication with Dr. Michele Schantz, NIST). Mass fraction concentrations (μg/kg)
were converted to urinary concentration (pg/mL) using a urine density value of 1.019 g/mL, as
specified on the COAs.
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The accuracy of the method was further assessed in a 6-point matrix standard
addition experiment. We spiked a urine pool with 10, 20, 50, 100, 500 and 1000
pg/mL of standards (four times higher spike for 1- and 2-NAP). The un-spiked and
spiked urine pools were analyzed, each in six replicates. A linear regression analysis
was carried out by plotting the measured concentrations against spiked
concentrations to evaluate correlations and determine concentrations of analyte in
the non-spiked urine sample. As shown in Table 11, the matrix-spiked samples gave
good linearity for all compounds with correlation coefficients ranging 0.92−1.00. The
intercept from the linear regression reflected 80−109% of the measured
concentrations in the un-spiked urine pool and the differences were not statistically
significant (alpha = 0.05), demonstrating a non-biased and accurate method.
Table 11. Matrix-spiked standard addition experiment parameters
Analyte

Slope

Intercept
(pg/mL)

r2

unspiked
Conc (pg/mL)

1-NAP

1.00

868

1.00

901

2-NAP

0.98

1208

1.00

1200

9-FLU

1.01

247

1.00

248

3-FLU

1.02

257

1.00

255

2-FLU

1.02

408

1.00

406

4-PHE

0.87

10

1.00

11

3-PHE

0.92

124

1.00

122

1-PHE

0.98

78

1.00

82

2-PHE

0.97

54

1.00

56

1-PYR

1.02

109

0.99

108

10. Quality Assessment and Proficiency Testing
a. Quality Assessment
Quality assessment procedures follow standard practices (6). Daily experimental
checks are made on the stability of the analytical system. Blanks and standards, as
well as QC materials, are added to each day's run sequence. The blank and
standard are analyzed at the beginning of each run to check the system for possible
contamination or in the spiking solutions and/or reagents. Two QCLs and two QCHs
are prepared and analyzed at the beginning and the end of each run; their
concentrations are compared with acceptance criteria to assure the proper operation
of the analysis. Relative retention times are examined for the internal standard to
ensure the choice of the correct chromatographic peak.
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b. Quality Control Procedures
1)

Individual Sample Quality Checks
Each individual sample will be subjected to a number of quality checks: a) auto
integrations must be reviewed and integrated manually if needed; b) the
calculated recovery for the spiked C13-labeled internal standards must be
above 15% and lower than 150%; c) the relative retention time of each analyte
in relation to its respective internal standard must be within ±0.15% (for OHPAHs) of its established value.

2)

Establishing QC limits
Quality control limits are established by characterizing assay precision with
repetitive analyses of the QC pools. Different variables are included in the
analysis (e.g. multiple analysts and instruments) to capture realistic assay
variation over time. The mean, standard deviation (within day and between
days), coefficient of variation, and confidence limits are calculated from this QC
characterization data set. Individual quality control charts for the
characterization runs are created, examined, and quality control limits are used
to verify assay precision and accuracy on a daily basis. QC characterization
statistics for OH-PAH analytes are listed in Table 9. The characterization
statistics are pool specific.

3)

Quality Control Evaluation
After the completion of a run, the quality control limits are evaluated to
determine if the run is “in control.” The quality control rules apply to the
average of the beginning and ending analyses of each of the QC pools. The
quality control results are evaluated according to Westgard rules (6).
Two QC pools per run with two or more QC results per pool
A) If both QC run means are within 2S m limits and individual results are within
2S i limits, then accept the run.
B) If 1 of the 2 QC run means is outside a 2S m limit - reject run if:
a) Extreme Outlier – Run mean is beyond the characterization mean +/4S m
b) 3S Rule - Run mean is outside a 3S m limit
c) 2S Rule - Both run means are outside the same 2S m limit
d) 10 X-bar Rule – Current and previous 9 run means are on same side of
the characterization mean
C) If one of the 4 QC individual results is outside a 2S i limit - reject run if:
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a) Extreme Outlier – One individual result is beyond the characterization
mean +/- 4S i
b) R 4S Rule – Within-run ranges for all pools in the same run exceed 4S w
(i.e., 95% range limit). Note: Since runs have multiple results per pool for
2 pools, the R 4S rule is applied within runs only.
Abbreviations:
S i = Standard deviation of individual results (the limits are not shown on the
chart unless run results are actually single measurements).
S m = Standard deviation of the run means (the limits are shown on the chart).
S w = Within-run standard deviation (the limits are not shown on the chart).
If the QC result for an analyte is declared “out of control”, the results of that
analyte for all patient samples analyzed during that run are invalid for reporting.
c. Proficiency Testing (PT)
1)

Scope of PT
The proficiency testing (PT) scheme for this method is administered by an inhouse PT coordinator. PT samples (4 different levels) were prepared in-house
by spiking a known amount of standard into a well characterized urine pool and
blind-coded by an in-house PT coordinator.
In addition, since 2013, we participate in the German External Quality
Assessment Scheme (G-EQUAS) for Analyses in Biological Materials, which
covers 1-NAP, 2-NAP and 1-PYR. G-EQUAS is organized and managed by
the Institute and Outpatient Clinic for Occupational, Social and Environmental
Medicine of the University of Erlangen-Nuremberg (Erlangen, Germany). The
program, evaluation, and certification are based on the guidelines of the
German Federal Medical Council.

2)

Frequency of PT
For the in-house PT scheme, five samples of unknown concentrations are
analyzed once or twice a year using the same method described for unknown
samples. The PT administrator will randomly select five of the PT materials for
analysis. A passing score is obtained if at least four of the five samples fall
within the prescribed limits established beforehand.
For G-EQUAS, two materials of unknown concentrations are sent from GEQUAS twice a year. The samples are analyzed using the same method
described for unknown samples and the results are reported to G-EQUAS for
evaluation and certification.
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Documentation of PT
For the in-house PT scheme, PT results are reviewed by the analyst and
laboratory supervisor, and then submitted to the in-house PT Coordinator. The
PT results are evaluated by the PT Coordinator; the analysis passes
proficiency testing if at least four of the five sample results deviate < 20% from
the known value.
For G-EQUAS, PT results are reviewed by the analyst and laboratory
supervisor. The results and QC report are approved by a DLS statistician,
Branch Chief, and DLS Director. The final results are submitted on G-EQUAS
website.
All proficiency results shall be appropriately documented. If the assay fails
proficiency testing then the sample preparation and instrumentation are
thoroughly examined to identify and correct the source of assay error.

11. Remedial Action if Calibration or QC Systems Fail to Meet Acceptable Criteria
If the calibration or QC systems fail to meet acceptable criteria, suspend all operations
until the source or cause of failure is identified and corrected. If the source of failure is
easily identifiable, for instance, failure of the mass spectrometer or a pipetting error, the
problem is immediately corrected. Otherwise, prepare fresh reagents and clean the
mass spectrometer system. Before beginning another analytical run, re-analyze several
QC materials (in the case of QC failure) or calibration standards (in the case of
calibration failure). After re-establishing calibration or quality control, resume analytical
runs. Document the QC failures, review the cases with supervisor to determine
source(s) of problem, and take measures to prevent re-occurrence of the same
problem.
12. Limitations of Method, Interfering Substances and Conditions
This method is an isotope dilution mass spectrometry method, widely regarded as the
definitive method for the measurement of organic toxicants in human body fluids. By
using tandem mass spectrometry, most interferences are eliminated. Due to the matrix
used in this procedure, occasional unknown interfering substances have been
encountered. If chromatographic interference with the native analyte or internal
standard occurs, reject that analysis. If repeat analysis still results in an interference
that cannot be separated chromatographically, the results for that analyte are not
reportable.
13. Reference Ranges (Normal Values)
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The reference range values for the OH-PAH metabolites, established based on the
National Health and Nutrition Examination Survey (NHANES), can be found at
http://www.cdc.gov/exposurereport.
14. Critical Call Results (“Panic Values”)
Insufficient data exist to correlate urinary OH-PAH concentrations with serious health
effects in humans. Therefore, no established “critical call” values exist. Test results in
this laboratory are reported in support of epidemiological studies, not for clinical
assessments.
15. Specimen Storage and Handling During Testing
Urine specimens may reach and maintain ambient temperature during analysis. The
urine extracts are stored in GC vials at -70 ºC after analysis. Current studies indicate
(CDC data) that the extracts are stable for at least three weeks.
16. Alternate Methods for Performing Test or Storing Specimens if Test System Fails
Alternate validated methods have not been evaluated for measuring these PAH
metabolites in urine. If the analytical system fails, urine extracts can be refrigerated
until the analytical system is restored to functionality. If long-term interruption (greater
than 4 weeks) is anticipated, then store urine specimens at -70 oC.
17. Test Result Reporting System; Protocol for Reporting Critical Calls (if Applicable)
Study subject data is reported in both concentration units (ng/L, pg/mL, parts per trillion,
or ppt) and adjusted based on creatinine excretion (ng/g creatinine).
a. The data from each analytical run are initially processed and reviewed by the
laboratory supervisor or Quality Control officer using MS Excel with build-in
macros to check sample Quality Control parameters, including recovery,
relative retention time, blank levels, calibration curve, etc. The supervisor
provides feedback to the analyst and/or his/her designee and requests
confirmation of the data as needed.
b. The Quality Control officer reviews each analytical run and identifies the quality
control samples within each analytical run and determines whether the
analytical run is performed under acceptable control conditions.
c. One of the Division statisticians reviews and approves the quality control charts
pertinent to the results being reported.
d. If the quality control data are acceptable, the laboratory supervisor or his/her
designee generates a memorandum to the Branch Chief, and a letter reporting
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the analytical results to the person(s) who requested the analyses to be signed
by the Division Director.
e. The data are sent (generally electronically by e-mail) to the person(s) that
made the initial request.
f. All data (chromatograms, etc.) are stored in electronic format.
Final hard copies of correspondence are maintained in the office of the Branch Chief
and/or his/her designee and with the quality control officer.
18. Transfer or Referral of Specimens; Procedures for Specimen Accountability and
Tracking
If greater than 1 mL of sample remains following successful completion of analysis, this
material must be returned to storage at -70 °C in case reanalysis is required. These
samples shall be retained until valid results have been obtained and reported and
sufficient time has passed for review of the results.
Standard record keeping (e.g., database, notebooks, and data files) is used to track
specimens. Specimens will only be transferred or referred to other DLS Branch
laboratories or, if required, to CLIA certified laboratories. Transfer is carried out through
the DLS Samples Logistic Group. Specimens may be stored at CDC specimen
handling and storage facility (CASPIR).
19. Summary Statistics and QC Graphs

See following pages

2009-2010 Summary Statistics and QC Chart for 1-naphthol

Lot

N

Start
Date

End
Date

Standard Coefficient of
Mean Deviation
Variation

QC6_201207a_URCP1H3 4 16JAN14 22JAN14 1181.38

44.79

3.8

QC6_201207b_URCP1H4 77 16JAN14 05AUG14 1139.10

52.95

4.6

QC5_201207a_URCP1L1 4 16JAN14 22JAN14 766.25

25.38

3.3

QC5_201207b_URCP1L3 77 16JAN14 05AUG14 755.16

36.90

4.9

QCL14F_URCP1L2

5 01AUG14 27AUG14 1112.20

31.33

2.8

QCM14F_URCP1M1

5 01AUG14 27AUG14 3496.60

159.83

4.6

2009-2010 Summary Statistics and QC Chart for 2-naphthol

Lot

N

Start
Date

End
Date

Standard Coefficient of
Mean Deviation
Variation

QC6_201207a_URCP2H3 4 16JAN14 22JAN14 2178.63

136.27

6.3

QC6_201207b_URCP2H4 80 16JAN14 31JUL14 2028.63

88.38

4.4

QC5_201207a_URCP2L1 4 16JAN14 22JAN14 1704.50

97.11

5.7

QC5_201207b_URCP2L3 80 16JAN14 31JUL14 1607.63

70.57

4.4

QCL14F_URCP2L2

4 01AUG14 27AUG14 1350.13

56.62

4.2

QCM14F_URCP2M1

4 01AUG14 27AUG14 3866.00

214.16

5.5

2009-2010 Summary Statistics and QC Chart for 3-fluorene

Lot

N

Start
Date

End
Date

Standard Coefficient of
Mean Deviation
Variation

QC6_201207a_URC03H3 4 16JAN14 22JAN14 628.88

28.32

4.5

QC6_201207b_URC03H4 80 16JAN14 31JUL14 586.10

41.78

7.1

QC5_201207a_URC03L1 4 16JAN14 22JAN14 243.25

15.25

6.3

QC5_201207b_URC03L3 80 16JAN14 31JUL14 229.97

17.31

7.5

QCL14F_URC03L2

4 01AUG14 27AUG14 254.63

20.93

8.2

QCM14F_URC03M1

4 01AUG14 27AUG14 736.25

62.72

8.5

2009-2010 Summary Statistics and QC Chart for 2-fluorene

Lot

N

Start
Date

End
Date

Standard Coefficient of
Mean Deviation
Variation

QC6_201207a_URCP4H3 4 16JAN14 22JAN14 615.38

15.35

2.5

QC6_201207b_URCP4H4 80 16JAN14 31JUL14 565.26

27.33

4.8

QC5_201207a_URCP4L1 4 16JAN14 22JAN14 301.13

10.74

3.6

QC5_201207b_URCP4L3 80 16JAN14 31JUL14 283.73

13.37

4.7

QCL14F_URCP4L2

4 01AUG14 27AUG14 254.25

12.25

4.8

QCM14F_URCP4M1

4 01AUG14 27AUG14 679.00

42.43

6.2

2009-2010 Summary Statistics and QC Chart for 3-phenanthrene

Lot

N

Start
Date

End
Date

Standard Coefficient of
Mean Deviation
Variation

QC6_201207a_URC05H3 4 16JAN14 22JAN14 555.75

3.71

0.7

QC6_201207b_URC05H4 79 16JAN14 31JUL14 516.72

20.84

4.0

QC5_201207a_URC05L1 4 16JAN14 22JAN14 209.50

4.67

2.2

QC5_201207b_URC05L3 79 16JAN14 31JUL14 201.82

10.54

5.2

QCL14F_URC05L2

4 01AUG14 27AUG14 171.13

8.89

5.2

QCM14F_URC05M1

4 01AUG14 27AUG14 506.38

29.24

5.8

2009-2010 Summary Statistics and QC Chart for 1-phenanthrene

Lot

N

Start
Date

End
Date

Standard Coefficient of
Mean Deviation
Variation

QC6_201207a_URC06H3 4 16JAN14 22JAN14 728.00

9.93

1.4

QC6_201207b_URC06H4 79 16JAN14 31JUL14 687.87

23.01

3.3

QC5_201207a_URC06L1 4 16JAN14 22JAN14 291.38

3.38

1.2

QC5_201207b_URC06L3 79 16JAN14 31JUL14 279.09

10.57

3.8

QCL14F_URC06L2

4 01AUG14 27AUG14 216.50

13.15

6.1

QCM14F_URC06M1

4 01AUG14 27AUG14 638.88

41.98

6.6

2009-2010 Summary Statistics and QC Chart for 2-phenanthrene

Lot

N

Start
Date

End
Date

Standard Coefficient of
Mean Deviation
Variation

QC6_201207a_URC07H3 4 16JAN14 22JAN14 718.25

7.88

1.1

QC6_201207b_URC07H4 76 16JAN14 31JUL14 669.76

22.02

3.3

QC5_201207a_URC07L1 4 16JAN14 22JAN14 277.88

5.98

2.2

QC5_201207b_URC07L3 76 16JAN14 31JUL14 264.05

10.85

4.1

QCL14F_URC07L2

7 01AUG14 27AUG14 212.50

9.05

4.3

QCM14F_URC07M1

7 01AUG14 27AUG14 621.14

24.12

3.9

2009-2010 Summary Statistics and QC Chart for 1-pyrene

Lot

N

Start
Date

End
Date

Standard Coefficient of
Mean Deviation
Variation

QC6_201207b_URC10H4 80 16JAN14 31JUL14 737.85

42.66

5.8

QC5_201207b_URC10L3 80 16JAN14 31JUL14 269.15

16.79

6.2

QC6_201207a_URC10H3 4 17JAN14 05FEB14 745.25

34.30

4.6

QC5_201207a_URC10L1 4 17JAN14 05FEB14 266.63

16.36

6.1

QCL14F_URC10L2

4 01AUG14 27AUG14 450.63

37.60

8.3

QCM14F_URC10M1

4 01AUG14 27AUG14 739.13

86.28

11.7

2009-2010 Summary Statistics and QC Chart for 9-fluorene

Lot

N

Start
Date

End
Date

Standard Coefficient of
Mean Deviation
Variation

QC6_201207a_URC17H3 4 16JAN14 22JAN14 672.75

43.08

6.4

QC6_201207b_URC17H4 80 16JAN14 31JUL14 646.03

33.69

5.2

QC5_201207a_URC17L1 4 16JAN14 22JAN14 405.63

20.29

5.0

QC5_201207b_URC17L3 80 16JAN14 31JUL14 387.01

16.89

4.4

QCL14F_URC17L2

5 01AUG14 27AUG14 207.10

8.50

4.1

QCM14F_URC17M1

5 01AUG14 27AUG14 560.60

46.65

8.3

2009-2010 Summary Statistics and QC Chart for 4-phenanthrene

Lot

Start
N Date

End
Standard Coefficient of
Date Mean Deviation
Variation

QC6_201207a_URC19H2 4 16JAN14 22JAN14 546.63

7.91

1.4

QC5_201207a_URC19L1 4 16JAN14 22JAN14 188.50

3.11

1.6
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Appendix A ─ Ruggedness Testing for Analytical Method
Procedure
Ruggedness testing was conducted to evaluate 5 parameters in this method: enzyme
amount, buffer strength, buffer pH value, de-conjugation time and de-conjugation
temperature. For each parameter, 3 or 5 levels were tested, including 1 or 2 lower level(s), 1
or 2 higher level(s), and the method level. An anonymous urine pool was used in the
ruggedness experiments. Samples were run in triplicates to ensure the precision of analytical
results. Reported below are results on the major detectable OH-PAH analytes.
Results in Tables
Enzyme amount
(mg/sample)

1-NAP 2-NAP 9-FLUO 3-FLUO 2-FLUO 4-PHEN 3-PHEN 1-PHEN 2-PHEN 1-PYR
Average concentration (pg/mL)

Lower level1

5mg

32664

38389

5682

1767

3062

390

1902

1701

1387

1288

Lower level2

9mg

33012

37555

5616

1763

3064

398

1864

1683

1371

1267

Method

10mg

33089

37914

5629

1759

3088

483

1868

1697

1373

1271

Higher level1 11mg

33915

39543

5641

1767

3062

489

1883

1703

1396

1291

Higher level2 20mg

33499

38383

5653

1785

3058

485

1891

1688

1385

1275

Standard deviation
Lower level1

5mg

20

432

120

5

18

10

24

12

5

15

Lower level2

9mg

97

249

256

34

24

7

9

15

3

11

Method

10mg

647

181

137

15

39

1

17

3

8

11

Higher level1 11mg

1118

281

99

26

31

13

32

21

9

17

Higher level2 20mg

312

312

90

13

21

3

10

10

4

27

Buffer strength
(M)

1-NAP 2-NAP 9-FLUO 3-FLUO 2-FLUO 4-PHEN 3-PHEN 1-PHEN 2-PHEN 1-PYR
average concentration (pg/mL)

Lower level1

0.5M

31599

35592

5706

1732

3087

492

1851

1735

1363

1221

Lower level2

0.9M

31708

36069

5684

1746

3028

452

1860

1711

1369

1231

Method

1M

31289

35629

5764

1753

3070

445

1856

1693

1368

1229

Higher level1

1.1M

31310

35516

5646

1753

3040

373

1860

1707

1350

1246

Higher level2

1.5M

32175

36013

5672

1751

3065

374

1843

1747

1358

1228

Standard deviation
Lower level1

0.5M

514

533

77

27

43

45

27

38

10

18

Lower level2

0.9M

1699

1429

145

20

17

31

25

65

23

23

Method

1M

537

580

79

22

47

16

47

32

18

24

Higher level1

1.1M

806

871

136

32

44

12

36

9

17

6

Higher level2

1.5M

1098

349

102

18

81

19

32

41

25

16
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1-NAP 2-NAP 9-FLUO 3-FLUO 2-FLUO 4-PHEN 3-PHEN 1-PHEN 2-PHEN 1-PYR
Average concentration (pg/mL)

Lower level1 pH4.5

26966

34660

5554

1774

2943

442

1878

1699

1374

1188

Lower level2 pH5.3

29123

35246

5757

1746

3061

401

1837

1671

1364

1290

Method

pH5.5

29221

36267

5773

1750

3101

467

1875

1699

1382

1263

Higher level1 pH5.7

28717

35474

5682

1729

3019

442

1856

1630

1363

1205

Higher level2 pH6.5

28169

36460

5863

1788

3112

440

1889

1632

1378

1243

Standard deviation
Lower level1 pH4.5

182

1675

77

118

8

20

10

22

15

29

Lower level2 pH5.3

920

718

42

21

26

50

37

17

11

23

Method

pH5.5

907

833

146

11

50

3

16

33

24

36

Higher level1 pH5.7

547

510

203

41

75

9

45

30

31

12

Higher level2 pH6.5

761

729

15

68

75

28

48

53

7

27

De-conjugation 1-NAP 2-NAP 9-FLUO 3-FLUO 2-FLUO 4-PHEN 3-PHEN 1-PHEN 2-PHEN 1-PYR
time (hours)
Average concentration (pg/mL)
Lower level1 4 hr

30121

39503

5721

1766

3111

478

1846

1690

1377

1246

Lower level2 17 hr 28590

34326

5516

1740

2982

429

1741

1631

1257

1226

Method

18 hr 28293

34936

5614

1721

2954

406

1756

1604

1268

1211

Higher level1 19 hr 27462

34265

5521

1710

2947

411

1724

1591

1263

1201

Higher level2 24 hr 28283

35314

5502

1729

2976

331

1769

1629

1288

1214

Standard deviation
Lower level1 4 hr

484

809

146

7

19

3

19

19

15

13

Lower level2 17 hr
Method

18 hr

261

330

74

19

36

6

21

21

22

36

921

1158

26

3

11

7

18

12

10

2

Higher level1 19 hr

1150

580

94

40

88

18

23

21

39

30

Higher level2 24 hr

861

983

162

11

28

4

40

26

10

12

De-conjugation
temperature (ºC)

1-NAP 2-NAP 9-FLUO 3-FLUO 2-FLUO 4-PHEN 3-PHEN 1-PHEN 2-PHEN 1-PYR
Average concentration (pg/mL)

Lower level

32ºC

28842

35031

5882

1681

3065

495

1752

1640

1355

1223

Method

37ºC

31709

37941

5601

1738

2985

416

1727

1568

1273

1196

Higher level

42ºC

28793

36394

5647

1730

2992

448

1813

1604

1341

1139

Standard deviation
Lower level

32ºC

694

1131

122

48

55

14

22

10

19

27

Method

37ºC

1771

2142

201

120

214

32

93

106

88

65

Higher level

42ºC

654

733

202

44

71

16

45

41

29

28
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Results in Graphs
Ruggedness Testing - 1-NAP
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Ruggedness Testing - 2-NAP
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Ruggedness Testing - 9-FLUO
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Ruggedness Testing - 3-FLUO
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Ruggedness Testing - 2-FLUO
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Ruggedness Testing - 4-PHEN
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Ruggedness Testing - 3-PHEN
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Ruggedness Testing - 1-PHEN
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Ruggedness Testing - 1-PYR
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Appendix B ─ Quick Method Guide
This quick method guide was compiled for new lab analysts to get familiar with the method
and for using in the lab for quick reference.
1. The current OH-PAH Method (as of September 2013)
The current method is a two-day method. Urine samples are aliquoted & spiked
on day one, deconjugated overnight, then extracted, evaporated, and derivatized
on day two.
2. Day One:
a. Print runsheet(s) of day’s run(s).
b. Pull samples out to thaw. Also thaw 2 QCL and 2 QCH per sample set.
c. Make sure that enough buffer/enzyme solution is prepared for the day’s samples.
If not, prepare additional solution.
d. Hand label culture tubes (2 sets, size 16x100) & conical tip centrifuge tubes
(15mL) with run ID #s. (Note: QCs are stored in culture tubes.)
e. Gently invert the urine specimen vial to ensure homogeneity. Aliquot 1mL urine
into test tubes. For blanks, use 1mL DI-water.
f. To all samples, add 1mL buffer/enzyme solution (recommend using Eppendorf
repeater pipette with 10mL tip) and 5uL ascorbic acid solution.
g. Load samples onto TRACY Gilson 215 Liquid Handler.
i. Transfer contents of one vial of IQS into clean amber V-vial & cap with new
septum. Weigh capped V-vial with IQS for “before” weight. Note on
runsheet.
ii. Purge transfer lines.
iii. Use TRACY to spike 40uL of IQS to all samples.
iv. Weigh capped V-vial with IQS for “after” weight.
v. Return any remaining IQS back to its GC vial. Write date on vial cap.
Return to refrigerator.
h. Cap all samples with solid black phenolic caps. Gently invert each sample twice to
mix the buffer and urine.
i. Incubate samples in 37°C oven overnight (~17-18) hours.
j. Record buffer solution # & date, enzyme # & date, IQS #, and any other
comments/observations on the runsheet.
3. Day Two:
a. Remove samples from incubation oven. Note time on runsheet.
b. Uncap tubes. Add DI-water to all samples (3mL, or enough to bring total volume in
test tube up to 5mL).
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c. Gilson 215 Liquid Handler
i. Place samples on Gilson 215 Liquid Handler automix. Lock lid. Power off
the automix, and then turn back on. Rotate automix until red “NOT READY’
light goes away.
ii. Load pre-labeled conical tip tubes & cover with aluminum foil.
iii. Fill solvent bottles with fresh 80/20 pentane/toluene.
iv. Check hexane level. Replace if necessary.
v. Check waste level. Replace if necessary.
vi. Open Trilution LH software. Log on as Administrator, no password is
required. The interface will open & default to the Liquid Handling menu.
vii. Click once on the Application bar to open the Application window.
viii. In the left pane, click the [+] next to Applications. Our method is OHPAH
Full Method. Double-click to select it.
ix. The top pane will load all the methods that make up the application. The
lower pane will show the Gilson 215 bed layout.
x. The default settings are for a batch of 20 samples, as shown in the ‘#Range
of Samples’ & ‘Number of Samples’ columns. If running more than 20
samples, you will need to change those entries.
xi. Return to the desktop & open Home818.exe. A small popup will appear. If
not already preset, enter Unit ID = 20 & the appropriate tilt (OMAR = 6 clicks
to the right; SIM = 15 clicks to the right). Click Send Calibration.
xii. Return to Application window.
xiii. Make sure all samples are loaded, the automix is properly locked, all
solution bottles are sufficiently filled, and all empty glass tubes are loaded in
the correct position.
xiv. Click RUN button in bottom left of window. A popup will ask to refresh the
run name. Click YES. The application will run.
xv. At first prompt, take samples out of automix & cap with solid caps. Return
to automix. Power off the automix, and then turn back on. Rotate automix
until red “NOT READY’ light goes away. Click OK on prompt.
xvi. After 5 minute mix, another prompt will appear. Move samples from
automix to the centrifuge. Centrifuge until 2 layers are clearly separated.
Usually, this needs two (2) 15-20 minute periods in the centrifuge.
xvii. Load samples back to automix rack UNCAPPED. Return rack to automix.
Power off the automix, and then turn back on. Rotate automix until red
“NOT READY’ light goes away. Click OK on prompt.
xviii. Turn on both RapidVaps to preheat.
xix. Repeat steps xv-xvii for second solvent extraction. Application will be
finished after this step.
d. Evaporate extracts in the RapidVaps.
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i. Spike 10uL dodecane into each sample, using Eppendorf repeater pipette &
0.1 mL tip.
ii. Load samples into preheated 45*C RapidVap and evaporate under 400450mbar vacuum at 40% rotation speed until ~1-2 mL remains. This step
takes ~10 minutes.
1. Note time on runsheet.
2. Print labels for your GC vials.
a. On SIM’s computer, open Brady LabelMark software. Choose
Part Family – Standard, Printer Type – TLS2200/TLS PC Link,
Label Part – PTL-72-461. Click OK.
b. Under the Tools menu, choose ‘Create Template.’ Type your
desired template info on the label. At the end of each line of
text, click the lock icon in the lower left corner. When done
creating template, click the save icon in the lower left corner.
Give template a name or overwrite an existing template.
Minimize the template.
c. Under the File menu, choose ‘Open Template’ and choose the
template you just created.
d. Above the labels are a row of buttons. Click the ‘SN’ button.
Enter the first sample number (1) and your last sample
number (most likely 40) then click ‘Generate.’ When you’ve
created all the labels you need for that set of samples, click
the printer icon to print.
3. Label your GC vials.
iii. Move extracts to 80*C RapidVap with 50% rotation speed and 200-230mbar
vacuum and evaporate until ~10uL remains.
1. This step will take roughly 25-30 minutes.
2. Use this time wisely: fill out runsheet, prep next set of samples, label
tomorrow’s glassware, start dishwasher, clean up, etc.
Using Eppendorf repeater, reconstitute samples by spiking 20uL Recovery
Standard (RS) into each tube. Vortex tubes for roughly 5 seconds.
Transfer extracts to labeled GC vials using electronic Rainin pipette.
Using Eppendorf repeater, spike 10uL MSTFA into all vials.
Displace air in MSTFA vial and GC vials using a gentle stream of Argon. Cap
vials.
Derivatize extracts in 60*C oven for 30 minutes. Use this time to fill out any
missing information on the runsheet.
When the extracts are ready, give them to the analyst. Make sure your runsheet is
complete before you give the samples to the analyst!
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Appendix C ─ Matrix and non-matrix calibration curve
comparison
Four different types of calibration curves were prepared. They are solvent based (current in
use), water-spiked, synthetic urine spiked, and urine-spiked calibration curves. The urinespiked curve is referred to matrix calibration curve, and the remaining three types of curves
are non-matrix curves. An experiment was set up to compare the slopes from these four
types of calibration curves, according to the DLS Policy and Procedure Manual (Version
February 27, 2012), Section 10.5.
Slope
3-fluo
1.10
1.08
1.09
1.08

2-fluo
1.15
1.14
1.14
1.14

4-phen
2.00
2.01
2.00
1.93

3-phen
1.36
1.36
1.36
1.36

1-phen
0.97
0.96
0.96
0.96

2-phen
0.94
0.94
0.94
0.93

1-pyr
1.36
1.31
1.31
1.31

% difference compared to urine-spiked curve
Solvent
3.5%
0.5%
1.4%
1.5%
Water
1.4%
0.6%
-0.4%
-0.1%
Syn-urine
3.2%
0.7%
-0.1%
0.2%
Urine
0.0%
0.0%
0.0%
0.0%

1.5%
0.4%
0.2%
0.0%

3.7%
4.2%
3.7%
0.0%

-0.3%
-0.1%
0.3%
0.0%

0.6%
-0.7%
-0.9%
0.0%

0.4%
0.2%
0.4%
0.0%

3.5%
-0.6%
-0.7%
0.0%

Solvent
Water
Syn-urine
Urine

1-nap
0.96
0.94
0.96
0.93

2-nap
0.89
0.89
0.89
0.89

9-fluo
0.99
0.97
0.97
0.97
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Appendix D ─ Method Comparison Graphs
Method comparison was performed by running 100 clinical samples using the previous
method by Thermo Quantum GC/MS/MS (Method #6703.03) and the updated method
(Method #6703.04) by Agilent GC/QQQ 7000 GC/MS/MS. The results are evaluated by both
the linear regression plots between the Thermo (“ZEUS”) and Agilent (“AGIL”) results, as well
as Bland-Altman plots by plotting the differences between the results from the two methods
against the mean of the two results.
Linear regression plots: New method “AGIL” vs. old method “ZEUS”
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Bland-Altman plots: Difference (AGIL-ZEUS) vs. Mean of AGIL and ZEUS
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Laboratory Procedure Manual
Analyte:

Monohydroxy-Polycyclic Aromatic
Hydrocarbons (OH-PAHs)
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Method:

Isotope Dilution Gas
Chromatography/High Resolution Mass
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Method No:
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Revised:
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as performed by:
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Important Information for Users
The Centers for Disease Control and Prevention (CDC) periodically refines these laboratory methods. It is the
responsibility of the user to contact the person listed on the title page of each write-up before using the analytical
method to find out whether any changes have been made and what revisions, if any, have been incorporated.
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This document details the Lab Protocol for NHANES 2003–2004 data.
A tabular list of the released analytes follows:
Data File
Name

Variable
Name

SAS Label

URXPO1

1-napthol (ng/L)

URXPO2

2-napthol

URXPO3

3-fluorene

URXPO4

2-fluorene

URXPO5

3-phenanthrene

URXPO6

1-phenanthrene

URXPO7

2-phenanthrene

URXP10

1-pyrene

URXP17

9-fluorene

URXP19

4-phenanthrene

l31pah_c

1
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1. Clinical Relevance and Summary of Test Principle
a. Clinical Relevance
Polycyclic aromatic hydrocarbons (PAHs) are a class of ubiquitous environmental
contaminants formed during incomplete combustion processes. Many of them have
been identified as suspected human carcinogens (1). Common routes of
occupational exposure may include work involving diesel fuels and coal tars such as
paving and roofing. Possible environmental exposures include smoking, diet, smog
and forest fires (2, 3). Application of this method to analyze samples obtained from
participants in the National Health and Nutrition Examination Survey (NHANES) will
help determining the reference range of these chemicals in general U.S. population,
aged 6 years and higher.
b. Test Principle
The specific analytes measured in this method are monohydroxy-PAH (OH-PAH).
The procedure involves enzymatic hydrolysis of urine, extraction, derivatization and
analysis using capillary gas chromatography combined with high resolution mass
spectrometry (GC-HRMS) (4, 5). This method uses isotope dilution with carbon-13
labeled internal standards. Ions from each analyte and each carbon-13 labeled
internal standard are monitored, and the abundances of each ion are measured.
The ratios of these ions are used as criteria for evaluating the data. The analytes
measured in this procedure are shown in Table 1. By evaluating these analytes in
urine, a measurement of the body burden from PAH exposure is obtained.
Table 1. Analytes measured, their parent compounds, and their abbreviations.

No.

Parent PAH

Metabolite/Analyte

Abbreviation

1

Naphthalene

1-hydroxynaphthalene

1-NAP

2

Naphthalene

2-hydroxynaphthalene

2-NAP

3

Fluorene

9-hydroxyfluorene

9-FLUO

4

Fluorene

2-hydroxyfluorene

2-FLUO

5

Fluorene

3-hydroxyfluorene

3-FLUO

6

Phenanthrene

1-hydroxyphenanthrene

1-PHEN

7

Phenanthrene

2-hydroxyphenanthrene

2-PHEN

8

Phenanthrene

3-hydroxyphenanthrene

3-PHEN

9

Phenanthrene

4-hydroxyphenanthrene

4-PHEN

11

Fluoranthene

3-hydroxyfluoranthene

3-FLRAN

2
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12
No.

2.

Pyrene

1-hydroxypyrene

Parent PAH

Metabolite/Analyte

1-PYR
Abbreviation

13

Benzo[c]phenanthrene

1-hydroxybenzo[c]phenanthrene 1-BCP

14

Benzo[c]phenanthrene

2-hydroxybenzo[c]phenanthrene 2-BCP

15

Benzo[c]phenanthrene

3-hydroxybenzo[c]phenanthrene 3-BCP

16

Benz[a]anthracene

1-hydroxybenz[a]anthracene

1-BAA

17

Benz[a]anthracene

3-hydroxybenz[a]anthracene

3-BAA

18

Benz[a]anthracene

9-hydroxybenz[a]anthracene

9-BAA

19

Chrysene

1-hydroxychrysene

1-CHRY

20

Chrysene

2-hydroxychrysene

2-CHRY

21

Chrysene

3-hydroxychrysene

3-CHRY

22

Chrysene

4-hydroxychrysene

4-CHRY

23

Chrysene

6-hydroxychrysene

6-CHRY

24

Benzo[a]pyrene

3-hydroxybenzo[a]pyrene

3-BAP

25

Benzo[a]pyrene

7-hydroxybenzo[a]pyrene

7-BAP

Safety Precautions
a. Reagent toxicity or carcinogenicity
Some of the reagents necessary to perform this procedure are toxic. Special care
must be taken to avoid inhalation or dermal exposure to the reagents necessary to
carry out the procedure.
b. Radioactive hazards
There are no radioactive hazards associated with this procedure.
c. Microbiological hazards
Although urine is generally regarded as less infectious than serum, the possibility of
being exposed to various microbiological hazards exists. Appropriate measures
must be taken to avoid any direct contact with the specimen (See Section 2.e.). CDC
recommends a Hepatitis B vaccination series and a baseline test for health care and
laboratory workers who are exposed to human fluids and tissues. Observe
Universal Precautions.
3
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d. Mechanical hazards
There are only minimal mechanical hazards when performing this procedure using
standard safety practices. Laboratorians must read and follow the manufacturer’s
information regarding safe operation of the equipment. Avoid direct contact with the
mechanical and electronic components of the mass spectrometer unless all power to
the instrument is off. Generally, mechanical and electronic maintenance and repair
must only be performed by qualified technicians. The autosampler and the mass
spectrometer contain a number of areas which are hot enough to cause burns.
Precautions must be used when working in these areas.
e. Protective equipment
Standard safety precautions must be followed when performing this procedure,
including the use of a lab coat/disposable gown, safety glasses, appropriate gloves,
and chemical fume hood. Refer to the laboratory Chemical Hygiene Plan and CDC
Division of Laboratory Sciences safety policies and procedures for details related to
specific activities, reagents, or agents.
f. Training
Formal training in the use of a high resolution mass spectrometer is necessary.
Users are required to read the operation manuals and must demonstrate safe
techniques in performing the method. Anyone involved in sample preparation must
be trained in all sample preparation equipment, chemical handling, and have basic
chemistry laboratory skills.
g. Personal hygiene
Follow Universal Precautions. Care must be taken when handling chemicals or any
biological specimen. Routine use of gloves and proper hand washing must be
practiced. Refer to the laboratory Chemical Hygiene Plan and CDC Division of
Laboratory Sciences safety policies and procedures for details related to specific
activities, reagents, or agents.
h. Disposal of wastes
Waste materials must be disposed of in compliance with laboratory, federal, state,
and local regulations. Solvents and reagents must always be disposed of in an
appropriate container clearly marked for waste products and temporarily stored in a
chemical fume hood. All disposable items that come in direct contact with the
biological specimens are to be placed in a biohazard autoclave bag that must be
kept in appropriate containers until sealed and autoclaved. The unshielded needles,
pipette tips and disposable syringes must be placed immediately into a sharps
container and autoclaved when this container becomes full. Wipe down all surfaces
with a freshly prepared bleach solution (a 10% dilution of commercial sodium
hypochlorite (bleach) or equivalent) when work is finished. Any non-disposable
4
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glassware or equipment that comes in contact with biological samples must be
washed with bleach solution before reuse or disposal. Any other non-disposable
glassware must be washed and recycled or disposed in an appropriate manner.
Observe Universal Precautions. Dispose of all biological samples and diluted
specimens in a brown glass bottle; disinfect the bio-hazardous material with bleach
(10% in final volume), and dispose according to CDC/DLS guidelines for disposal of
hazardous waste. Dispose all used disposable laboratory supplies (tubes, pipette tips,
etc.) in an autoclave bag at the end of the analysis according to CDC/DLS guidelines
for disposal of hazardous waste.

3.

Computerization; Data-System Management
a. Software and knowledge requirements
This method has been validated using the Thermo Finnigan GC/HRMS system
controlled by XcaliburTM Software 1.3. Analyte peaks are integrated by Quan
Browser under XcaliburTM. Results are exported from Quan Browser result files to
Microsoft Excel files that are subsequently used for calculations. Final results are
stored in Excel format. Knowledge of and experience with these software packages
(or their equivalent) is required to utilize and maintain the data management
structure.
b. Sample information
Information pertaining to particular specimens is entered into the database either
manually or electronically transferred. The result file is transferred electronically into
the database. No personal identifiers are used, and all samples are referenced to a
blind coded sample identifier.
c. Data maintenance
All sample and analytical data are checked prior to being entered into the MS Excel
for transcription errors and overall validity. The database is routinely backed up
locally through the standard practices of the NCEH network. The local area network
manager must be contacted for emergency assistance.
d. Information security
Information security is managed at multiple levels. The information management
systems that contain the final reportable results are restricted through user ID and
password security access. The computers and instrument systems that contain the
raw and processed data files require specific knowledge of software manipulation
techniques and physical location. Site security is provided at multiple levels through
restricted access to the individual laboratories, buildings, and site. Confidentiality of
5
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results is protected by referencing results to blind coded sample IDs (no names or
personal identifiers have used).

4.

Procedures for Collecting, Storing, and Handling Specimens; Criteria for
Specimen Rejection
a. Special instructions
No special instructions such as fasting or special diets are required.
b. Sample collection
Urine specimens are collected from subjects in standard urine collection cups.
Samples must be refrigerated as soon as possible, and must be transferred to
specimen vials within 24 hours of collection. A minimum of 5 milliliters of urine is
collected and poured into sterile vials with screw-cap tops. The specimens are then
labeled, frozen immediately to -20 ºC, and stored on dry ice for shipping. Special
care must be taken in packing to protect vials from breakage during shipment. All
samples in long-term storage must be kept at -70 ºC until analysis.
c. Sample handling
In general, urine specimens must be transported and stored at frozen (< -10 ºC).
Once received, they can be frozen at -70 ± 10 °C until time for analysis. Portions of
the sample that remain after analytical aliquots are withdrawn must be refrozen at
-70 ± 10 °C. Samples are not compromised by repeated freeze and thaw cycles.
d. Sample quantity
The minimum amount of specimen required for analysis is 0.5 mL, with the optimal
amount being 2.0 mL.
e. Unacceptable specimens
Specimens must be frozen at a minimum of -20 ± 5 °C when delivered to the lab.
The minimum volume required is 0.5 mL. If either of these criteria is violated, then
specimen must be rejected. Specimens are also rejected if suspected of
contamination due to improper collection procedures or devices. Specimen
characteristics that may compromise test results include contamination of urine by
contact with dust, dirt, etc. from improper handling. Samples with visible
microbiological growth (e.g. mold, bacteria) must also be rejected. In all cases,
request a second urine specimen if available. A description of reasons for each
rejected sample must be recorded on the sample transfer sheet, such as low sample
volume, leaking or damaged container.
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5.

Procedures for Microscopic Examinations; Criteria for Rejecting Inadequately
Prepared Slides
Not applicable for this procedure.

6.

Preparation of Reagents, Calibration Materials, Control Materials, and all Other
Materials; Equipment and Instrumentation
a. Reagents and sources
See Table 2.
Table 2. Reagents and the Respective Manufacturers

Reagent

Manufacturers*

organic de-ionized water (D.I. H2O)

Prepared in house, CDC (Aqua Solutions,
Inc.)

β-glucuronidase/arylsulfatase, H-1, powder
enzyme

Sigma Chemical, St. Louis, MO

pentane, hexane, acetonitrile, toluene, and
methanol (ABSOLV grade)

Tedia Company, Fairfield, OH

glacial acetic acid

Sigma Chemical, St. Louis, MO

sodium acetate

Sigma Chemical, St. Louis, MO

N-methyl-N-(trimethylsilyl)trifluoroacetamide (MSTFA)

Sigma Chemical, St. Louis, MO

argon, nitrogen

Air Products and Chemicals, Allentown, PA

13

C6 1-NAP

Synthesized in house, CDC

13

C6 1-PYR, 13C6 3-FLRAN,

TerraChem, Merriam, KS

13

C6 3-PHEN, 13C6 6-CHRY, 13C6 1-BAA,
C6 3-BAP, 13C6 4-OH-PCB79

Cambridge Isotope Laboratories, Andover,
MA

13

Reagent

Manufacturers*

13

C6 2-FLUO, 13C6 3-BCP, 13C6 3-CHRY

ChemSyn, Lenexa, KS

13

C6 3-FLUO, 13C6 9-FLUO, 13C6 2-PHEN

Los Alamos National Laboratory, Los
Alamos, NM

1-NAP, 2-NAP, 2-FLUO, 3-FLUO, 9FLUO, 1-PYR

Sigma-Aldrich Chemicals, St. Louis, MO
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1-PHEN, 2-PHEN, 3-PHEN, 4-PHEN

Promochem, Wesel, Germany

3-FLRAN, 1-BCP, 2-BCP, 3-BCP, 1-BAA,
3-BAA, 9-BAA, 1-CHRY, 2-CHRY, 3CHRY, 4-CHRY, 6-CHRY, 3-BAP, 7-BAP

Midwest Research Institute, NCI, Kansas
City, MO

* Equivalent products from other manufacturers may be used.
b. Preparation of Reagents
1)

1 mol/L Sodium Acetate Buffer
Place 41 g sodium acetate in a 500-mL volumetric flask and add about 300 mL
de-ionized water (D.I. H2O). Swirl solution to dissolve sodium acetate. Fill flask
to the 500 mL line with D.I. H2O. Adjust the pH to 5.5 with glacial acetic acid.

2)

N-methyl-N-(trimethylsilyl)-trifluoroacetamide (MSTFA)
Open the sealed vial containing MSTFA from the vendor and place the MSTFA
solution in an amber screw-cap vial (2-mL). Displace the air over the MSTFA
with a gentle stream of argon. The MSTFA can be stored in the microreaction
vessel for up to 1 month. To add MSTFA to multiple samples, use an
Eppendorf repeator pipette with a 100-μL pipette tip, set the pipette volume at
10 μL, and then withdraw 100 μL of MSTFA. Discard the first two aliquots and
the last aliquot of MSTFA (10 μL per aliquot), aliquot 10 μL into each of the
sample vials.

c. Preparation of Calibration Materials
All OH-PAH are light sensitive and precautions to minimize exposure to light must
be taken, such as use of UV-filtered yellow light in lab areas where samples
1)

Stock Solutions of Individual Analytes (100 ng/μL, 400 ng/μL for 1- and 2-NAP)
Approximately 5-10 mg of neat standard is weighed into a silanized screw cap
amber vial. Add 3 mL of acetonitrile into the vial and record the exact weight of
the solvent. Allow the OH-PAH to dissolve by gentle swirling or placing in an
ultrasonic bath. Dilute the individual standards using toluene to 100 ng/μL (400
ng/μL for 1- and 2-NAP) with a final volume of 3.0 mL. All solutions are stored
in a -70 ºC freezer with an inert argon atmosphere in the vials.

2)

Working Standard Solution of 24 native OH-PAH mix (W.S.A)
Combine 400 μL from each of the 24 native OH-PAH standard stock solutions
in a silanized screw cap amber vial to generate the working standard solution
(W.S.A, 4 ng/μL for each native OH-PAH concentration, except for 1- and 28

OH-PAH in Urine
NHANES 2003-2004

NAP at 16 ng/μL). Homogenize the mixture by gentle swirling and vortexing.
Solutions of other concentrations may also be prepared, if needed. Displace air
in the vial with argon, cap the vials, and stored them at -70 ºC until needed.
3)

Working Standard Solution of 13 C13-labeled OH-PAH mix (W.S.I)
Combine 3.76 mL of acetonitrile and 480 μL of each of the 13 13C-labeled OHPAH standard stock solutions (90 ng/μL) in a silanized screw cap amber vial to
generate the working internal standard solution (W.S.I, 4 ng/μL for each of the
13 13C-labeled OH-PAHs). Homogenize the mixture by gentle swirling and
vortexing. Displace air in the vial with argon, cap the vials, and stored them at 70 ºC until needed.

4)

External Calibration Standards (E.C.S)
External calibration standards (E.C.S.) are prepared as presented in Table 3
below. Concentrations for 1- and 2-NAP in all standards are 4 times higher than
the rest of the native compounds, because these two compounds are present
in urine samples at high concentrations. Concentrations for 13C-labeled internal
standards are 100 pg/μL in all calibration standards.
Table 3. Preparation of external calibration standards (ECS)
Analytes, excluding 1- & 2-NAP
1- and 2- NAP
Standard
Equivalent
Equivalent
Concentration
Concentration
No.
concentration in
concentration in
(pg/μL)
(pg/μL)
urine (pg/mL)
urine(pg/mL)
0
0.5
5
20
2
1
1
10
40
4
2

2

20

8

80

3

5

50

20

200

Analytes, excluding 1- & 2-NAP
1- and 2- NAP
Standard
Equivalent
Equivalent
Concentration
Concentration
No.
concentration in
concentration in
(pg/μL)
(pg/μL)
urine (pg/mL)
urine (pg/mL)
4
10
100
400
40
5
50
500
2,000
200
6

100

1,000

400

4,000

7

500

5,000

2,000

20,000

8

1000

10,000

4,000

40,000

9

2000

20,000

8,000

80,000
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10
5)

4000

40,000

16,000

160,000

Internal Qualification Standards (I.Q.S)
Measure 5.0 mL of W.S.I into a 200-mL silanized volumetric flask. Dilute the
solution with toluene to the 200-mL line to get the internal qualification standard
(I.Q.S). The concentration of each 13C-labeled OH-PAH is 100 pg/μL. Aliquot
1.7 mL of I.Q.S. into amber 2-mL standard vials, cap and seal the vials with
Argon. Store all I.Q.S. vials in the fridge until use.

6)

Mass Spectrometric Check Solution
This solution is used daily to monitor the operating performance of the GC
column and the mass spectrometer. A solution of 20 fg/μL of a tetrachlorinated dioxin is used as the check solution. For a 1 μL injection, a
minimum signal-to-noise of 4 on the m/z 321.894 peak must be obtained.

d. Preparation of Control Materials
1)

Quality Control (QC) materials
Prepare quality control materials by spiking a known amount of native OH-PAH
mixture (in acentonitrile) into 2000 mL of an anonymous filtered urine pool (500
pg/mL urine). Homogenize the QC solutions overnight for equilibration. On the
next day aliquot the QC solutions into 16 x 100 mm test tubes (3 mL in each
tube) and store them at -70 ± 10 °C until use.

2)

Recovery Spiking Solution (R.S.S)
Approximately 3 mg of neat 13C6 4-OH-PCB79 is weighed into a silanized
screw cap amber vial. Add 3 mL of toluene into the vial and record the exact
weight of the solvent. Allow the standard to dissolve by gentle swirling or
placing in an ultrasonic bath. Methylate the standard using dioazomethane to
obtain its methylated derivative 13C6 4-MeH-PCB79. Dilute the methylated
standard solution using toluene to 200 pg/μL. This will be used as the recovery
spiking solution (R.S.S.). Aliquot 1.7 mL of E.R.S. into amber 2-mL standard
vials, cap and seal the vials with Argon. Store all E.R.S. vials at 4 ± 5 °C until
use.

3)

Proficiency Test Material (PT)
Prepare quality control materials by spiking a known amount of W.S.A (at a
different level as the QC) into 100 mL of an anonymous urine pool (filtered) to
achieve the target concentration. Prepare the urine pools at levels within the
linear range of the method. After spiking the urine pool with a known amount of
W.S.A, homogenize the PT solutions overnight for equilibration. On the next
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day aliquot the PT solutions into 16 x 100 mm test tubes (3 mL in each tube)
and store them at -70 ± 10 °C until use.
e. Other equipment, materials, and supplies
Materials / supplies and sources used during the development, validation, and
application of this method are listed below. Materials / supplies procured from other
sources must meet or exceed these specifications.
•

Gilson 215 liquid handler (Gilson Inc., Middleton, WI)

•

818 Automix mixer (Gilson Inc., Middleton, WI)

•

Water bath/sonicator (Branson Ultrasonics, Danbury, CT)

•

TurboVap LV evaporator (Caliper LifeSciences, Hopkinton, MA)

•

Incubator ovens (Fisher Scientific)

•

pH meter (Thermo)

•

Microbalance (Mettler-Toledo)

•

Stirring/heating plates (Corning)

•

Miscellaneous glassware (Pyrex, Kimax, Wheaton or Corning)

•

Eppendorf Repeater Plus Pipette (Brinkmann Instruments Inc., Westbury,
NY).

•

Rainin Electronic Pipettes (Rainin, California)

•

Pasteur pipettes and bulbs (VWR).

•

Maxi-mix Vortex mixer (Barnstead International)

•

Allegra-6 centrifuge (Beckman-Coulter)

•

Amber screw top vials with various volume (Supelco, Inc., Bellefonte, PA)

•

Clear autosampler vials, 0.5 mL (SunSri)

f. Instrumentation
The analyses are performed on a ThermoFinnigan MAT-95XL high resolution mass
spectrometer (Finnigan MAT, San Jose, CA) equipped with an electron impact
ionization and interfaced to an Agilent Technologies 6890 gas chromatograph (GC)
system (Agilent Technologies, Palo Alto, CA)
1)

Gas chromatograph configuration
Chromatographic separation is performed on an Agilent 6890 gas
chromatograph fitted with a J&W DB-5 30-m fused silica capillary column. The
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column ID is 0.25-mm and the film thickness is 0.25-micron (J&W, # 22-5022 or
equivalent). The temperature program lasts a total of 23 minutes. (See Table 4
for GC configuration and Table 5 for the GC temperature program.)
Table 4. GC Configuration
GC Parameter

Setting

Carrier gas

Helium

Constant flow rate

1 mL/minute

GC purge flow rate

70 mL/minute

GC saver time

5 minutes

GC save flow rate

15 mL/minute

Injection mode

Splitless

Injector purge delay

2 minutes

Injector temperature

270 ºC

Table 5. GC Temperature Program

2)

Time (min.)

Temperature (ºC)

0

95

2

95

6

160

Time (min.)

Temperature (ºC)

20

295

21

320

25

320

High Resolution Mass spectrometer (HRMS) configuration
Thermo Finnigan MAT 95XL HRMS configuration is presented in Table 6. The
mass spectrometer is operated under Multiple Ion Detection (MID) mode. The
masses used to quantify analytes are presented in Table 7.
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Table 6. Thermo Finnigan MAT 95XL HRMS Configuration
HRMS Parameter

Setting

Scan mode

Multiple ion detection

Ionization type

Electron impact

Ion polarity mode

Positive

Electron energy

45 eV

Resolution

10,000

Ion source

250 ºC

Conversion dynode voltage

Positive

Electron multiplier voltage

1.45 – 2.25 kV (or 106 gain)

Table 7. Analyte Masses
Analyte

Molecular Ion
[M.+]

Confirmation Ion
[M.+-15]

1-NAP, 2-NAP

216.0970

201

2-FLUO, 3-FLUO, 9-FLUO

254.1127

239

1-PHEN, 2-PHEN, 3-PHEN, 4-PHEN

266.1127

251

3-FLRAN, 1-PYR

290.1127

275

3-BAP

340.1283

325

Molecular Ion
[M.+]

Confirmation Ion
[M.+-15]

316.1283

301

Analyte
1-BCP, 2-BCP, 3-BCP, 1-BAA, 3-BAA, 9BAA, 1-CHRY, 2-CHRY, 3-CHRY, 4-CHRY,
6-CHRY
13

C6 1-NAP

222.1172

207

13

C6 2-FLUO, 13C6 3-FLUO, 13C6 9-FLUO

260.1328

245

13

C6 3-PHEN, 13C6 2-PHEN

272.1328

257

13

C6 3-FLRAN, 13C6 1-PYR

272.1328

257
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13

C6 3-CHRY, 13C6 6-CHRY, 13C6 1-BAA, 13C6
3-BCP

7.

296.1328

281

Calibration and Calibration Verification
a. Calibration of Mass Spectrometer
Calibrate and tune the Finnigan MAT 95XL mass spectrometer using FC43
(perfluorotributylamine) according to the instructions in the operator’s manual
located next to the instrument. After calibrated with 10,000 resolution and maximum
sensitivity, the instrument is prepared for the analysis of OH-PAHs as described in
Section 8.
b. Creation of calibration curve
1)

Calculation data
A linear calibration curve, using eight ECS with concentration ranging from 1 to
1000 pg/μL, is generated using the ratio of the peak area of the analyte to the
labeled internal standard. The concentrations in ECS correspond to 10 10,000 pg/mL (40-40,000 pg/mL) levels in 2 mL urine. For urine samples with
concentrations higher than the calibration curve, the highest two standards
(2000 & 4000 pg/ μL, 8,000 and 16,000 pg/μL for 1-&2-NAP) are prepared to
extend the calibration curve and to accurately quantify those samples.

2)

Evaluation of curve statistics
The R-squared value of the curve must be equal to or greater than 0.990.
Linearity of the standard curve must extend over the entire standard range.

3)

Use of the calibration curve
The lowest point on the calibration curve is the lowest reportable level and the
highest point is above the expected range of results. The remainders of the
points are distributed between these two extremes, with the majority of points in
the concentration range where most unknowns fall.

c. Calibration verification
In order to verify that this calibration of this test system is accurate and stable
throughout reportable range, three E.C.S from a different batch are analyzed every
six months. Calculated concentration must be within 10% deviation from expected
concentration.
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8.

Procedure Operation Instructions; Calculations; Interpretation of Results
An analytical run consists of two blanks, two QCs, and 16 unknown urine samples.
a. Sample Preparation
All samples were prepared in a laboratory with non-UV yellow fluorescent lights.
1)

Hydrolysis
Allow urine samples and QCs to thaw and reach room temperature. Aliquot 2
mL of urine sample (or 2 mL of D.I. H2O as blank) into a 16x100 mm test tube.
Add 10 μL of I.Q.S, 1 mL of 1 M sodium acetate butter (pH = 5.5) containing βGlucuronidase/ arylsulfatase enzyme from Helix pomatia (10 mg enzyme/1 mL
buffer) into the test tube. Turn the test tube gently several times to mix well.
Place the caps on the tube and incubate the sample at 37 ºC overnight.

2)

Automated Liquid-Liquid Extraction
Add D.I. water (2 mL) to the sample, and extract the sample twice with pentane
using the Gilson 215 liquid handler (Gilson Inc., Middleton, WI) for automation.
Place the sample in the automix tray and initiate the extraction procedure. The
automated procedure starts with adding pentane (5 mL) to the sample and
mixing the sample by rotating it in the automix for 5 minutes (20 rpm). Then the
procedure is paused and the sample is centrifuged at 2800 rpm on an
AllegraTM 6 centrifuge (Beckman Coulter Inc., Fullerton, CA) for 20 minutes.
After returning the samples to the automix tray, resume the procedure and a
probe transfers the organic phase to clean collection tubes. This extraction
procedure is repeated again with additional pentane (5 mL).

3)

Evaporation
Sample extract is spiked with 5 μL dodecane and placed in a TurboVap LV
evaporator. Under a stream of N2 and in a 40 ºC water bath, the sample is
evaporated to ~5 μL within 10-15 minutes. Spike 20 μL toluene and 5 μL R.S.S
into the sample tube, vortex the sample, and transfer the contents to clear
autosampler vial.

4)

Derivatization
Add 10 μL of MSTFA into the GC vial and then displace the air in the vial with a
gentle stream of argon. Quickly screw a cap onto the vial. Place the vials in an
incubator or oven set at 60 ºC for 30 minutes. The samples are then ready for
analysis on the mass spectrometer. The samples may also be stored in a
refrigerator for up to 1 week.

b. Instrument and software setup for the GC/HRMS
15
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1)

Preliminary MAT 95 system setup and performance check
Turn on the MAT 95, inject 2 μL FC-43 into the reference inlet. In the TUNE
window, adjust resolution between 9900 and 10100. Perform a GC/HRMS
analysis of the mass spectrometer check solution (2, 3, 7, 8-TCDD, 10 fg/μL,
1 μL injection) and verify chromatographic resolution and peak intensity. In the
lab note book, record the signal to noise of the check compound.

2)

Final setup and operation
a) Create the run sequence
In the Xcalibur Sequence Setup window, create a sequence for the run
using the template. Make sure that the appropriate number of samples is
loaded, the appropriate filenames are assigned, and the appropriate sample
positions on the autosampler tray are included in the run sequence. Make
sure that the correct process method and instrument method are selected.
The latter defines GC, MID, Autosampler, and ICL methods. The methods
used are listed in Table 8.
Table 8. GC/HRMS Methods
Program

Method

Instrument

NHANES0304.met

GC

pah_deriv.mcr

MID

pah_deriv.mid

Autosampler

pah_1ul.mcs

Program

Method

ICL

Sleep90.icl 5

Process

NHANES0304.pmd

Filenames conform to the following format: PMYYNNN or KMYYNNN where
P = PAH samples run on the MAT 95 instrument named as CASSI, K =
PAH samples run on the MAT 95 instrument named as MIKE; M = month (A
= January, B = February, C = March, etc.); YY = year (04 = year 2004), and
NNN = run number for the month. For example, the filename PB01012
corresponds to PAH-February-2001-sample #12 run on MAT 95 – CASSI,
and KD02267 would correspond to PAH-April-2002-sample #267 run on
MAT 95 – MIKE.
b) Start the sequence
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Click Run Sequence in the main menu under Action. Verify the sequence
set up and make sure the whole sequence instead of one single sample is
selected to be run. Click OK; the system will immediately start by turning
green on the first sample to run.
3)

System standby
To place the MAT 95 in standby mode, enter the command .bye at the ICL
prompt. This command turns off the accelerator, multiplier and dynode voltage,
and vents the reference compound (FC-43). To reactivate the MAT 95, enter
.run 0.50 at the command prompt. Add the reference compound and tune.

c. Processing of data
After the run sequence finishes, process all raw data files in the whole sequence
using the “NHANES0304.pmd” process method after which the analyte peaks in
data files are automatically integrated using the process method. Visually review
and manually correct if needed the integration of each peak in the QuanBrowser
window of the Xcalibur software. Save the reviewed result file, export it as a MS
Excel file, and save the Excel file on the Q:\ share drive. Perform all further
calculations such as standard curve generation, QC analysis, blank analysis, limit-ofdetection determination, unknown sample calculations, data distribution, etc. in MS
Excel and in SAS. Import final results and all supporting information into an RBase
database located on the Q:\ share drive.
3-BAA and 9-BAA co-elute in the GC chromatograms, so they are reported together
as 3_9-BAA. 3-FLRAN had an interfering peak in the GC chromatograms; therefore,
3-FLRAN is not reported.
d. Replacement and Periodic Maintenance of Key Components
1)

MAT 95 XL Mass Spectrometer
•
•
•
•
•

2)

Check cooling water level and temperature monthly
Clean the ion volume or replace it monthly
Clean the ion source or replace it annually
Replace the calibration gas septum monthly
Trained Thermo Finnigan technicians perform all other maintenance based
on an annual schedule, or as needed

Agilent 6890 GC
•
•
•
•
•

Change the injection port liner and septum daily
Clean the injection port, clean or replace the gold seal monthly
Cut the GC column for ~10” monthly or as needed
Replace the GC column at 1000 analyses or sooner
Replace Helium tank when the pressure is below 500 psi.
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Note: Accelerate the above maintenance schedules if necessary.

9.

Reportable Range of Results
The linear range of the standard calibration curves determines the highest and lowest
analytical values of an analyte that are reportable. The calibration verification of the
method encompasses this reportable range. However, urine samples with analytical
data values exceeding the highest reportable limit may be re-extracted using a smaller
volume and re-analyzed so that the result is in the reportable range.
a. Linearity Limits
Analytical standards were linear for all analytes through the range of concentrations
evaluated. The linear range for all analytes except 1-NAPH and 2-NAPH is 5 pg/mL
to 40,000 pg/mL. Calibration curves for 1-NAPH and 2-NAPH are extended to
160,000 ng/L, because their high concentrations detected from unknown samples.
Therefore, the linear range for 1-NAPH and 2-NAPH were 20 pg/mL to 160,000
pg/mL. Urine samples whose concentrations exceed these ranges must be diluted
and re-analyzed using a smaller aliquot.
b. Limit of Detection
The limit of detection (LOD) for this method is defined as the higher LOD calculated
by two methods: (i) in direct relation to method blanks prepared in parallel with the
unknown samples, as 3 times the standard deviation of the method blanks, and (ii)
according to the instrumental detection limit defined as the lowest point in the
calibration curve (0.5 pg/uL, or 5 pg/mL in 2-mL urine samples) verified to give a
signal with the S/N equal to or greater than 3. The detection limits determined for the
analytes are presented in Table 9.
Table 9. Limits of Detection (LODs)

Analyte
1-NAP

LOD (pg/mL)
18

2-NAP

12

9-FLUO

3.9

2-FLUO

4.5

3-FLUO

6.9

1-PHEN

2.6

2-PHEN

3.8

3-PHEN

2.6

4-PHEN

3.7
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1-PYR

4.9

1-BCP

2.8

1-BAA

2.6

3_9-BAA
1-CHRY

5.2
2.6

2-CHRY

2.6

3-CHRY

2.6

4-CHRY

2.6

6-CHRY
3-BAP

2.6
2.6

7-BAP

2.6

c. Precision
The precision of the method is reflected in the variance of quality control samples
analyzed over time. The coefficients of variation (CV) of the method over analyses
of six batches of QC samples (N=42) are listed in Table 10 below. These QC
samples were prepared over 3 weeks by four different analysts using two automated
liquid handlers and two GC/HRMS instruments.

Table 10. Mean Concentration and CV for 42 QC samples

Analyte

Mean (pptr)

CV (%)

1-NAP

1584

2.9

2-NAP

2912

3.3

9-FLUO

596

2.9

2-FLUO

559

3.0

3-FLUO

485

2.8

1-PHEN

391

4.4

2-PHEN

606

3.5

3-PHEN

533

3.2

4-PHEN

531

3.9

1-PYR

542

3.4
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1-BCP

925

8.0

2-BCP

559

3.3

3-BCP

522

3.0

1-BAA

528

2.7

3_9-BAA

843

10

1-CHRY

496

11

2-CHRY

565

4.4

3-CHRY

510

3.3

4-CHRY

468

6.7

6-CHRY

509

4.5

3-BAP

686

6.6

7-BAP

772

8.5

d. Analytical specificity
The HRMS system provides excellent analytical specificity. The analyte peaks are
located in well defined regions of the chromatogram with no visible interferences and
low background. The observation of confirmation ions (M-15 ions) confirms the
presence of analytes of interest. In addition, the retention time for the analytes
relative to the isotope internal standards give additional confirmation of the presence
of analytes in the sample.
e. Accuracy
Presently no established standard reference material (SRM) exists for OH-PAHs in
human urine. Therefore, we cannot evaluate the accuracy of this method by
analyzing an SRM and compare to its certified concentrations. Nonetheless, the
usage of isotopically labeled internal standards can adjust for any deviates occurred
on the OH-PAH analytes during sample preparation and instrumental analysis, and
thus provide assurance on the accuracy of this method.

10. Quality Assessment and Proficiency Testing
a. Quality Assessment
Quality assessment procedures follow standard practices6. Daily experimental
checks are made on the stability of the analytical system. Blanks and standards, as
well as QC materials, are added to each day's run sequence. The blank and
standard are analyzed at the beginning of each run to check the system for possible
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contamination or in the spiking solutions and/or reagents. Two QCs are prepared
and analyzed with each run; their concentrations are compared with acceptance
criteria to assure the proper operation of the analysis. Relative retention times are
examined for the internal standard to ensure the choice of the correct
chromatographic peak.
b. Quality Control Procedures
1)

Establishing QC limits
Quality control limits are established by characterizing assay precision with
repetitive analyses of the QC pool. Different variables are included in the
analysis (e.g. different analysts and instruments) to capture realistic assay
variation over time. The mean, standard deviation, coefficient of variation, and
confidence limits are calculated from this QC characterization data set.
Individual quality control charts for the characterization runs are created,
examined, and quality control limits are used to verify assay precision and
accuracy on a daily basis. Typical QC characterization statistics for OH-PAH
analytes are listed in Table 11.
Table 11. QC Characterization Statistics

Analyte

Mean - 3σ
(pptr)

Mean - 2σ
(pptr)

Mean
(pptr)

1-NAP

2950

3146

3536

3927

4123

2-NAP

2201

2359

2677

2995

3153

2-FLUOR

563

583

624

664

684

3-FLUOR

444

460

493

527

543

9-FLUOR

575

599

647

695

719

1-PHEN

336

357

398

439

459

2-PHEN

489

507

542

577

595

3-PHEN

492

515

560

606

628

4-PHEN

433

468

537

606

641

1-PYR

489

507

544

581

599

2-BCP

420

458

534

611

649

3-BCP

460

476

508

540

557

1-BAA

451

473

517

561

583

3-9-BAA

446

592

885

1178

1324

2-CHRY

359

399

479

559

599

3-CHRY

457

477

517

557

577
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2)

4-CHRY

399

435

506

577

613

6-CHRY

402

433

497

560

592

3-BAP

228

328

528

727

827

7-BAP

99

291

676

1060

1253

Quality Control evaluation
After the completion of a run, the quality control limits are consulted to
determine if the run is “in control”. The quality control rules apply to the
average of the beginning and ending analyses of each of the QC pools. The
quality control results are evaluated according to Westgard rules (6):
a) If both of the QCs are within the 2σ limits, then accept the run.
b) If one of two QC results is outside the 2σ limits, then apply the rules below
and reject the run if any condition is met.
i. Extreme outliner: the result is outside the characterization mean by more
than 4σ limit.
ii. 13σ – Average of both QCs is outside of a 3σ limit.
iii. 22σ –QC results from two consecutive runs are outside of 2σ limit on the
same side of the mean.
iv. R4σ sequential –QC results from two consecutive runs are outside of 2σ
limit on opposite sides of the mean.
v. 10x sequential – QC results from ten consecutive runs are on the same
side of the mean.
If the QC result for an analyte is declared “out of control”, the results of that
analyte for all patient samples analyzed during that run are invalid for reporting.

c. Proficiency Testing (PT)
1)

Scope of PT
There are no established PT materials; currently we are the only laboratory
running this essay. Therefore, the proficiency testing (PT) scheme for this
method is administered by an in-house PT coordinator. Because no standard
reference materials exist for urinary analysis of hydroxy-PAH levels, PT
samples are prepared in-house by spiking a known amount of standard into a
well characterized urine pool, and blink-coded by in-house PT coordinator.

2)

Frequency of PT
Four samples of unknown PT concentrations are analyzed twice a year using
the same method described for unknown samples. Proficiency testing must be
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performed a minimum of once every 6 months. The PT administrator will
randomly select five of the PT materials for analysis. A passing score is
obtained if at least four of the five samples fall within the prescribed limits
established beforehand.
3)

Documentation of PT
Analytical PT results are reviewed by the analyst and laboratory supervisor,
and then submitted to the in-house PT Coordinator. The PT results are
evaluated by the PT Coordinator; the analysis passes proficiency testing if at
least four of the five sample results deviate < 20% from the known value. All
proficiency results shall be appropriately documented. If the assay fails
proficiency testing then the sample preparation and instrumentation are
thoroughly examined to identify and correct the source of assay error.

11. Remedial Action if Calibration or QC Systems Fail to Meet Acceptable Criteria
If the calibration or QC systems fail to meet acceptable criteria, suspend all operations
until the source or cause of failure is identified and corrected. If the source of failure is
easily identifiable, for instance, failure of the mass spectrometer or a pipeting error, the
problem is immediately corrected. Otherwise, prepare fresh reagents and clean the
mass spectrometer system. Before beginning another analytical run, re-analyze several
QC materials (in the case of QC failure) or calibration standards (in the case of
calibration failure). After re-establishing calibration or quality control, resume analytical
runs. Document the QC failures, review the cases with supervisor to determine
source(s) of problem, and take measures to prevent re-occurrence of the same
problem.

12. Limitations of Method, Interfering Substances and Conditions
This method is an isotope dilution mass spectrometry method, widely regarded as the
definitive method for the measurement of organic toxicants in human body fluids. By
using high resolution mass spectrometry, most interference is eliminated. Due to the
matrix used in this procedure, occasional unknown interfering substances have been
encountered. If chromatographic interference with the internal standards occurs, reject
that analysis. If repeat analysis still results in an interference with the internal standard,
the results for that analyte are not reportable.

13. Reference Ranges (Normal Values)
Population-based reference ranges for 23 OH-PAH analytes were determined from a
subset of National Health and Nutritional Survey (NHANES) 2001-2002 urine samples.
The reference values are presented in Table 12.
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Table 12. Reference values from NHANES 2001-2002 (95% confidence interval in
parentheses)
Urine Concentration (ng/L)

Analyte

N

1-NAP

2748

2-NAP

2748

2-FLUO

2745

3-FLUO

2745

9-FLUO

2745

Analyte

N

1-PHEN

2741

2-PHEN

2742

3-PHEN

2741

4-PHEN

2741

1-PYR

2747

1-BCP

2732

2-BCP

2748

3-BCP

2748

1-BAA

2748

3_9-BAA

2748

1-CHRY

2748

2-CHRY

2748

Creatinine Adjusted
Concentration (ng/g crea.)
th
Median
95
Median
95th
2050
22300
1910
17800
(1790-2340) (18000-26600) (1700-2160) (14500-20800)
2470
26000
2310
16700
(2110-2890) (22500-29700) (1980-2300) (14100-19200)
318
2820
298
1890
(277-366)
(2340-3450)
(361-340)
(1590-2290)
134
1620
125
1060
(115-155)
(1390-1900)
(108-144)
(909-1290)
219
1090
205
852
(191-251)
(950-1300)
(183-229)
(736-1120)
Urine Concentration (ng/L)
Creatinine Adjusted
Concentration (ng/g crea.)
Median
95th
Median
95th
140
684
132
464
(125-158)
(581-763)
(118-147)
(404-539)
54.0
332
50.6
231
(46.0-63.5)
(299-377)
(43.3-59.2)
(206-275)
105
649
98.0
428
(92.5-118)
(542-747)
(87.4-110)
(360-621)
41.9
280
39.2
347
(31.3-56.0)
(250-339)
(29.6-52.0)
(293-411)
49.6
349
46.4
243
(43.4-56.7)
(290-400)
(40.9-52.8)
(206-269)
34.0
41.3
<LOD
<LOD
(16.0-54.0)
(21.0-70.8)
13.0
20.3
<LOD
<LOD
(6.00-20.0)
(15.9-23.3)
11.0
15.9
<LOD
<LOD
(8.00-16.0)
(14.9-16.7)
30.0
27.0
<LOD
<LOD
(22.0-36.0)
(19.6-32.4)
24.0
31.8
<LOD
<LOD
(19.0-31.0)
(28.4-35.5)
105
89.2
<LOD
<LOD
(85.0-138)
(71.4-104)
31.0
27.8
<LOD
<LOD
(14.0-45.0)
(20.9-35.0)
24

OH-PAH in Urine
NHANES 2003-2004

3-CHRY

2748

<LOD

4-CHRY

2748

<LOD

6-CHRY

2736

<LOD

3-BAP

2748

<LOD

42.0
(36.0-46.0)
<LOD
77.0
(57.0-101)
179
(139-251)

<LOD
<LOD
<LOD
<LOD

56.8
(47.4-62.5)
<LOD
61.5
(47.7-76.4)
184
(147-248)

14. Critical Call Results (“Panic Values”)
It is unlikely that any result would be a "critical call", which would only be observed in
acute poisonings. There are no established “critical call” values. Application of this
method to NHANES studies will assist in determining levels of OH-PAH normally found
in healthy US populations. Test results in this laboratory are reported in support of
epidemiological studies, not clinical assessments. Data will help determine critical
exposures.

15. Specimen Storage and Handling During Testing
Urine specimens may reach and maintain ambient temperature during analysis. The
urine extracts are stored in GC vials in a -70 ºC freezer after analysis. Current studies
indicate (CDC data) that the extracts are stable for three weeks.

16. Alternate Methods for Performing Test or Storing Specimens if Test System Fails
Alternate validated methods have not been evaluated for measuring OH-PAH in urine.
If the analytical system fails, then samples must be refrigerated (at 4 ± 3 oC) until the
analytical system is restored to functionality. If long-term interruption (greater that 4
weeks) is anticipated, then store urine specimens at -70 ± 10 oC.
The method is designed to run on a GC/HRMS instrument, and is not generally
transferable to other instrumentation. If the system fails, then samples must be
refrigerated (at 4 ± 3 oC) until the analytical system is restored to functionality. If longterm interruption (greater that 4 weeks) is anticipated, then store urine specimens at -70
± 10 oC. Sample extracts in GC vials may be refrigerated for as long as three weeks. If
long-term interruption is anticipated, store sample extracts at -70 ± 10 oC.

17. Test Result Reporting System; Protocol for Reporting Critical Calls (if Applicable)
Study subject data is reported in both concentration units (ng/L) and adjusted based on
creatinine excretion (µg/g creatinine).
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Once the validity of the data is established by the QC/QA system outlined above, these
results are verified by a DLS statistician, and the data reported in both hard copy and
electronic copy. This data, a cover letter, and a table of method specifications and
reference range values will be routed through the appropriate channels for approval (i.e.
supervisor, branch chief, division director) as outlined in the DLS policy and procedure
manual. After approval at the division level, the report will be sent to the contact person
who requested the analyses.

18. Transfer or Referral of Specimens; Procedures for Specimen Accountability and
Tracking
If greater than 1 mL of sample remains following successful completion of analysis, this
material must be returned to storage at -70 ± 10 °C in case reanalysis is required.
These samples shall be retained until valid results have been obtained and reported
and sufficient time has passed for review of the results.
Standard record keeping (e.g., database, notebooks, and data files) is used to track
specimens. Specimens will only be transferred or referred to other DLS Branch
laboratories or, if required, to CLIA certified laboratories. Transfer is carried out through
the DLS Samples Logistic Group. Specimens may be stored at CDC specimen
handling and storage facility (CASPIR).
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19. Summary Statistics and QC Graphs
A. 1-naphthol
Summary Statistics for 1-naphthol by Lot

Lot
QC

N
157

Start Date
12/2/2005

End Date
3/30/2006

Mean
3540.24

Standard
Deviation
188.83

Coefficient of
Variation
5.3

2003-2004 1-naphthol Quality Control
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B. 2-naphthol
Summary Statistics for 2-naphthol by Lot

Lot
QC

N
156

Start Date
12/2/2005

End Date
3/30/2006

Mean
2676.16

Standard
Deviation
157.34

Coefficient of
Variation
5.9

2003-2004 2-naphthol Quality Control
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C. 3-fluorene
Summary Statistics for 3-fluorene by Lot

Lot
QC

N
153

Start Date
12/2/2005

End Date
3/30/2006

Mean
492.08

Standard
Deviation
14.53

Coefficient of
Variation
3.0

2003-2004 3-fluorene Quality Control

600
575
550
QC

525
500
475
450
425
400
375
350
325
300
275
250
225
200
175
150
125
100
75
50
25
0
12/2/2005

12/22/2005

1/11/2006

1/31/2006

29

2/20/2006

3/12/2006

OH-PAH in Urine
NHANES 2003-2004

D. 2-fluorene
Summary Statistics for 2-fluorene by Lot

Lot
QC

N
153

Start Date
12/2/2005

End Date
3/30/2006

Mean
621.75

Standard
Deviation
17.1

Coefficient of
Variation
2.7

2003-2004 2-Fluorene Quality Control
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E. 3-phenanthrene
Summary Statistics for 3-phenanthrene by Lot

Lot
QC

N
148

Start Date
12/2/2005

End Date
3/30/2006

Mean
560.38

Standard
Deviation
18.91

Coefficient of
Variation
3.4

2003-2004 3-phenanthrene Quality Control
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F. 1-phenanthrene
Summary Statistics for 1-phenanthrene by Lot

Lot
QC

N
150

Start Date
12/2/2005

End Date
3/30/2006

Mean
397.58

Standard
Deviation
18.16

Coefficient of
Variation
4.6

2003-2004 1-phenanthrene Quality Control
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G. 2-phenanthrene
Summary Statistics for 2-phenanthrene by Lot

Lot
QC

N
152

Start Date
12/2/2005

End Date
3/30/2006

Mean
541.17

Standard
Deviation
15.22

Coefficient of
Variation
2.8

2003-2004 2-phenanthrene Quality Control

600
QC

575
550
525
500
475
450
425
400
375
350
325
300
275
250
225
200
175
150
125
100
75
50
25
0
12/2/2005

12/22/2005

1/11/2006

1/31/2006

33

2/20/2006

3/12/2006

OH-PAH in Urine
NHANES 2003-2004

H. 1-pyrene
Summary Statistics for 1-pyrene by Lot

Lot
QC

N
152

Start Date
12/2/2005

End Date
3/30/2006

Mean
544.21

Standard
Deviation
17.79

Coefficient of
Variation
3.3

2003-2004 1-pyrene Quality Control
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I. 9-fluorene
Summary Statistics for 9-fluorene by Lot

Lot
QC

N
152

Start Date
12/2/2005

End Date
3/30/2006

Mean
646.52

Standard
Deviation
21.14

Coefficient of
Variation
3.3

2003-2004 9-fluorene Quality Control
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J. 4-phenanthrene
Summary Statistics for 4-phenanthrene by Lot

Lot
QC

N
149

Start Date
12/2/2005

End Date
3/24/2006

Mean
538.52

Standard
Deviation
27.18

Coefficient of
Variation
5.0

2003-2004 4-phenanthrene Quality Control
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